[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2653
1. Bamberger JD, Unick J, Klein P, Fraser M, Chesney M, Katz MH: Helping the urban poor stay with antiretroviral HIV drug therapy. Am J Public Health; 2000 May;90(5):699-701
HIV InSite. treatment guidelines - Adherence to HIV Antiretroviral Therapy .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Helping the urban poor stay with antiretroviral HIV drug therapy.
  • Recent studies have documented dramatic decreases in opportunistic infections, hospitalizations, and mortality among HIV-infected persons, owing primarily to the advent of highly active antiretroviral medications.
  • Unfortunately, not all segments of the population living with HIV benefit equally from treatment.
  • In San Francisco, only about 30% of the HIV-infected urban poor take combination highly active antiretroviral medications, as compared with 88% of HIV-infected gay men.
  • Practitioners who care for the urban poor are reluctant to prescribe these medications, fearing inadequate or inconsistent adherence to the complicated medical regimen.
  • Persons typically must take 2 to 15 pills at a time, 2 to 3 times a day.
  • Some of the medications require refrigeration, which may not be available to the homeless poor.
  • Therefore, they may have difficulty adhering to instructions to take medications only on an empty stomach or with food.
  • Lack of a safe place to store medications may be an issue for some.
  • In addition, many urban poor live with drug, alcohol, or mental health problems, which can interfere with taking medications as prescribed.
  • Inconsistent adherence to medication regimens has serious consequences.
  • Patients do not benefit fully from treatments, and they will become resistant to the medications in their regimen as well as to other medications in the same classes as those in their regimen.
  • Concern that the urban poor will not adhere to highly active antiretroviral medication regimens has led to debate on the role of clinicians and public health officials in determining who can comply with these regimens.
  • Rather than define the characteristics that would predict adherence to these regimens, the San Francisco Department of Public Health created a program to support adherence among those who may have the greatest difficulty complying with complicated highly active antiretroviral medication regimens.
  • [MeSH-major] Anti-HIV Agents / economics. HIV Infections / drug therapy. HIV Infections / psychology. Health Planning Support / organization & administration. Patient Compliance / psychology. Poverty / economics. Poverty / psychology. Urban Health Services / organization & administration
  • [MeSH-minor] Adult. CD4 Lymphocyte Count. Drug Costs. Female. Health Care Costs / statistics & numerical data. Health Services Research. Homeless Persons / psychology. Humans. Male. Program Evaluation. San Francisco. Viral Load


2. Casaretto L, Sousa PL, Mari JJ: Chemotherapy versus support cancer treatment in advanced gastric cancer: a meta-analysis. Braz J Med Biol Res; 2006 Apr;39(4):431-40
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy versus support cancer treatment in advanced gastric cancer: a meta-analysis.
  • The aim of the present study was to compare the efficacy of chemotherapy and support treatment in patients with advanced non-resectable gastric cancer in a systematic review and meta-analysis of randomized clinical trials that included a comparison of chemotherapy and support care treatment in patients diagnosed with gastric adenocarcinoma, regardless of their age, gender or place of treatment.
  • 1) randomized clinical trials and antineoplastic combined therapy or gastrointestinal neoplasm, 2) stomach neoplasm and drug therapy, 3) clinical trial and multi-modality therapy, 4) stomach neoplasm and drug therapy or quality of life, 5) double-blind method or clinical trial.
  • Five studies fulfilled the inclusion criteria, for a total of 390 participants, 208 (53%) receiving chemotherapy, 182 (47%) receiving support care treatment and 6 losses (1.6%).
  • The 1-year survival rate was 8% for support care and 20% for chemotherapy (RR = 2.14, 95% CI = 1.00-4.57, P = 0.05); 30% of the patients in the chemotherapy group and 12% in the support care group attained a 6-month symptom-free period (RR = 2.33, 95% CI = 1.41-3.87, P < 0.01).
  • Quality of life evaluated after 4 months was significantly better for the chemotherapy patients (34%; RR = 2.07, 95% CI = 1.31-3.28, P < 0.01) with tumor mass reduction (RR = 3.32, 95% CI = 0.77-14.24, P = 0.1).
  • Chemotherapy increased the 1-year survival rate of the patients and provided a longer symptom-free period of 6 months and an improvement in quality of life.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16612465.001).
  • [ISSN] 0100-879X
  • [Journal-full-title] Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
  • [ISO-abbreviation] Braz. J. Med. Biol. Res.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Meta-Analysis; Review
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 27
  •  go-up   go-down


3. Spector R, Vesell ES: The power of pharmacological sciences: the example of proton pump inhibitors. Pharmacology; 2006;76(3):148-55; discussion 156

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The power of pharmacological sciences: the example of proton pump inhibitors.
  • Critics have questioned the foundational principles of pharmacological sciences and modern drug therapy; they also claim that drug therapy is often too expensive or of uncertain value.
  • Yet the US government began to pay for drug therapy under Medicare in 2006, an explicit recognition of the value of modern drug therapy.
  • To clarify this confusion, we review the philosophical and scientific foundations of pharmacology, drug discovery and development, the attendant strategies and successful results.
  • We also review and answer the major attacks on the philosophical and scientific foundations of modern pharmacology and drug therapy.
  • Finally, we define the characteristics of an ideal drug.
  • As an example of the principles and strategies of modern pharmacological sciences and their successful application, we focus on the discovery and development of proton pump inhibitors (PPIs) of stomach acid production.
  • This class of drugs approaches the ideal and exemplifies successful application of modern pharmacological principles to drug discovery and development.
  • Moreover, the use of PPIs as a pharmacological tool allowed the resolution of important scientific questions, e.g., the role of stomach acid in peptic diseases of the stomach, duodenum and esophagus.
  • [MeSH-major] Drug Therapy / methods. Proton Pump Inhibitors. Technology, Pharmaceutical / methods
  • [MeSH-minor] Drug Costs. Forecasting. Gastroesophageal Reflux / drug therapy. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 16449824.001).
  • [ISSN] 0031-7012
  • [Journal-full-title] Pharmacology
  • [ISO-abbreviation] Pharmacology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Proton Pump Inhibitors
  •  go-up   go-down


Advertisement
4. Bar-Sela G, Tsalic M, Steiner M, Wollner M, Haim N: Local recurrence following adjuvant chemotherapy without radiotherapy in completely resected stomach and gastroesophageal junction adenocarcinoma. Anticancer Res; 2009 May;29(5):1853-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local recurrence following adjuvant chemotherapy without radiotherapy in completely resected stomach and gastroesophageal junction adenocarcinoma.
  • BACKGROUND: The gold standard of adjuvant treatment after surgical resection of adenocarcinoma of the stomach or gastroesophageal junction (GEJ) is chemoradiotherapy.
  • We retrospectively evaluated chemotherapy without radiotherapy in stomach and GEJ adenocarcinoma, using a combination of etoposide, adriamycin and cisplatin (modified EAP).
  • The median survival for the entire group was 20 months, with a median time to recurrence of 11 months.
  • CONCLUSION: Our data cast doubt on the benefit of radiotherapy adjuvant to chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Chemotherapy, Adjuvant. Neoplasm Recurrence, Local. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19443416.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


5. Summerton NA, Welch RW, Bondoc L, Yang HH, Pleune B, Ramachandran N, Harris AM, Bland D, Jackson WJ, Park S, Clements JD, Nabors GS: Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxin. Vaccine; 2010 Feb 3;28(5):1404-11
MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No vaccine exists for the prevention of infection with the ubiquitous gastric pathogen Helicobacter pylori, and drug therapy for the infection is complicated by poor patient compliance, the high cost of treatment, and ineffectiveness against drug-resistant strains.
  • A new medical advancement is required to reduce the incidence of peptic ulcer disease and stomach cancer, two conditions caused by infection with H. pylori.
  • Additionally, following a challenge infection, the dmLT-adjuvanted vaccine was as effective as single mutant LT in reducing gastric urease levels (diagnostic for H. pylori infection), and H. pylori colonization in the stomach as assessed by quantitative analysis of stomach homogenates.
  • A lyophilized formulation of HWC was developed to improve stability and to potentially reduce reliance on cold chain maintenance.
  • It was observed that a dmLT-adjuvanted lyophilized vaccine was equally as protective in the mouse model as the liquid formulation as assessed by gastric urease analysis and analysis of stomach homogenates for viable H. pylori.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Elsevier Ltd. All rights reserved.
  • [Cites] Infect Immun. 1995 May;63(5):1617-23 [7729864.001]
  • [Cites] Vaccine. 1995 Jan;13(1):22-8 [7539199.001]
  • [Cites] Infect Immun. 1995 Sep;63(9):3731-5 [7642317.001]
  • [Cites] Int J Epidemiol. 1995 Oct;24(5):875-87 [8557443.001]
  • [Cites] Lancet. 1996 Jun 8;347(9015):1630-1 [8667902.001]
  • [Cites] Gastroenterology. 1997 Apr;112(4):1386-97 [9098027.001]
  • [Cites] Infect Immun. 1997 Dec;65(12):4996-5002 [9393788.001]
  • [Cites] J Infect Dis. 1997 Dec;176 Suppl 2:S183-8 [9396708.001]
  • [Cites] Infect Immun. 1998 Jun;66(6):2879-86 [9596763.001]
  • [Cites] Vaccine. 1998 Jan;16(1):33-7 [9607006.001]
  • [Cites] Vaccine. 1998 Aug;16(13):1336-43 [9682399.001]
  • [Cites] Aliment Pharmacol Ther. 1998 Feb;12 Suppl 1:61-71 [9701004.001]
  • [Cites] Gastroenterology. 1998 Nov;115(5):1272-7 [9797384.001]
  • [Cites] J Exp Med. 1998 Dec 21;188(12):2277-88 [9858514.001]
  • [Cites] Gastroenterology. 1999 Apr;116(4):804-12 [10092302.001]
  • [Cites] Aliment Pharmacol Ther. 1999 Mar;13(3):303-9 [10102962.001]
  • [Cites] Vaccine. 1999 Mar 5;17(9-10):1130-5 [10195624.001]
  • [Cites] Vaccine. 1999 Oct 14;18(5-6):449-59 [10519934.001]
  • [Cites] Gut. 2006 Dec;55(12):1711-6 [16603633.001]
  • [Cites] FEMS Immunol Med Microbiol. 2007 Jul;50(2):146-56 [17442014.001]
  • [Cites] Curr Protoc Immunol. 2001 May;Chapter 19:Unit 19.8 [18432759.001]
  • [Cites] Gastroenterology. 2008 Sep;135(3):787-95 [18619971.001]
  • [Cites] Gut. 2002 Nov;51(5):634-40 [12377799.001]
  • [Cites] Infect Immun. 2000 Apr;68(4):2135-41 [10722611.001]
  • [Cites] Arch Med Res. 2000 Sep-Oct;31(5):431-69 [11179581.001]
  • [Cites] Scand J Immunol. 2001 May;53(5):437-42 [11309150.001]
  • [Cites] Infect Immun. 2001 Jun;69(6):3581-90 [11349017.001]
  • [Cites] Vaccine. 2001 Dec 12;20(5-6):845-52 [11738748.001]
  • [Cites] Infect Immun. 2002 Nov;70(11):6383-8 [12379718.001]
  • [Cites] Vaccine. 2002 Dec 13;21(3-4):194-201 [12450694.001]
  • [Cites] Vaccine. 2003 Jan 17;21(5-6):562-5 [12531656.001]
  • [Cites] Vaccine. 2004 Jun 2;22(17-18):2273-7 [15149786.001]
  • [Cites] Vaccine. 2004 Jun 30;22(20):2541-6 [15193379.001]
  • [Cites] Infect Immun. 1975 Feb;11(2):334-6 [1089601.001]
  • [Cites] Lancet. 1990 May 26;335(8700):1233-5 [1971318.001]
  • [Cites] Cancer. 1990 Dec 15;66(12):2569-74 [2249197.001]
  • [Cites] Gastroenterology. 1991 Jun;100(6):1495-501 [2019355.001]
  • [Cites] Infect Immun. 1991 Jul;59(7):2470-5 [2050411.001]
  • [Cites] BMJ. 1991 Jun 1;302(6788):1302-5 [2059685.001]
  • [Cites] N Engl J Med. 1991 Oct 17;325(16):1127-31 [1891020.001]
  • [Cites] N Engl J Med. 1991 Oct 17;325(16):1132-6 [1891021.001]
  • [Cites] Ann Intern Med. 1992 May 1;116(9):705-8 [1558340.001]
  • [Cites] Cancer. 1993 Jan 15;71(2):297-301 [8422620.001]
  • [Cites] Infect Immun. 1994 Aug;62(8):3594-7 [8039937.001]
  • [Cites] Scand J Gastroenterol Suppl. 1994;201:2-6 [8047819.001]
  • [Cites] Science. 1995 Mar 17;267(5204):1655-8 [7886456.001]
  • (PMID = 19897067.001).
  • [ISSN] 1873-2518
  • [Journal-full-title] Vaccine
  • [ISO-abbreviation] Vaccine
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / AI060624-02; United States / NIAID NIH HHS / AI / U01 AI060624-03; United States / NIAID NIH HHS / AI / U01 AI060624-02; United States / NIAID NIH HHS / AI / U01 AI060624; United States / NIAID NIH HHS / AI / U01 AI060624-01; United States / NIAID NIH HHS / AI / 5U01AI060624; United States / NIAID NIH HHS / AI / AI060624-03; United States / NIAID NIH HHS / AI / AI060624-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Bacterial Toxins; 0 / Bacterial Vaccines; 0 / Enterotoxins; 0 / Escherichia coli Proteins; 0 / Vaccines, Inactivated; 0 / heat-labile enterotoxin, E coli
  • [Other-IDs] NLM/ NIHMS157649; NLM/ PMC2814929
  •  go-up   go-down


6. Thomas AL, O'Byrne K, Steward WP: Chemotherapy for upper gastrointestinal tumours. Postgrad Med J; 2000 Jun;76(896):321-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy for upper gastrointestinal tumours.
  • The aim of this review is to identify current chemotherapy treatment for tumours of the oesophagus, stomach, pancreas, and liver.
  • The role of both neoadjuvant, adjuvant, and palliative chemotherapy regimens will be discussed.
  • This review will be of interest to oncologists in clarifying current issues regarding chemotherapy, and to physicians in other medical specialties, to increase their general understanding of benefits and drawbacks of chemotherapy in this patient group.
  • [MeSH-major] Gastrointestinal Neoplasms / drug therapy
  • [MeSH-minor] Carcinoma, Hepatocellular / drug therapy. Chemotherapy, Adjuvant. Esophageal Neoplasms / drug therapy. Humans. Liver Neoplasms / drug therapy. Palliative Care / methods. Pancreatic Neoplasms / drug therapy. Radiotherapy, Adjuvant. Stomach Neoplasms / drug therapy. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1441-7 [8336183.001]
  • [Cites] Ann Oncol. 1993 Apr;4(4):333-6 [8518226.001]
  • [Cites] J Natl Cancer Inst. 1994 Jul 20;86(14):1086-91 [7912736.001]
  • [Cites] Br J Surg. 1994 Jun;81(6):882-5 [8044610.001]
  • [Cites] Invest New Drugs. 1994;12(1):29-34 [7960602.001]
  • [Cites] N Engl J Med. 1996 Aug 15;335(7):462-7 [8672151.001]
  • [Cites] Ann Oncol. 1996 Apr;7(4):347-53 [8805925.001]
  • [Cites] Invest New Drugs. 1996;13(4):355-8 [8824356.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):261-7 [8996151.001]
  • [Cites] Ann Surg. 1997 May;225(5):621-33; discussion 633-6 [9193189.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] BMJ. 1998 Jun 27;316(7149):1935-8 [9641928.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2733-8 [9704725.001]
  • [Cites] Ann Oncol. 1998 Sep;9(9):951-62 [9818067.001]
  • [Cites] Lancet. 1969 Oct 25;2(7626):865-7 [4186452.001]
  • [Cites] Br Med J. 1980 Dec 13;281(6255):1589-91 [7004559.001]
  • [Cites] J Clin Oncol. 1985 Mar;3(3):373-8 [3973648.001]
  • [Cites] Radiother Oncol. 1984 Oct;2(3):179-88 [6084856.001]
  • [Cites] J Clin Oncol. 1987 Apr;5(4):622-8 [3559653.001]
  • [Cites] Cancer Treat Rev. 1988 Mar;15(1):1-31 [2834053.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Jan;16(1):67-72 [2463980.001]
  • [Cites] J Clin Oncol. 1990 Jan;8(1):119-27 [2295902.001]
  • [Cites] J Clin Oncol. 1990 Aug;8(8):1362-9 [2199622.001]
  • [Cites] J Clin Oncol. 1991 May;9(5):827-31 [2016625.001]
  • [Cites] N Engl J Med. 1992 Jun 11;326(24):1593-8 [1584260.001]
  • [Cites] Br J Surg. 1993 Mar;80(3):384-6 [8472160.001]
  • [Cites] World J Surg. 1993 Mar-Apr;17(2):256-61; discussion 261-2 [8511923.001]
  • [Cites] Lancet. 1994 May 28;343(8909):1309-12 [7910321.001]
  • (PMID = 10824043.001).
  • [ISSN] 0032-5473
  • [Journal-full-title] Postgraduate medical journal
  • [ISO-abbreviation] Postgrad Med J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] ENGLAND
  • [Number-of-references] 20
  • [Other-IDs] NLM/ PMC1741601
  •  go-up   go-down


7. Greenson JK: Gastrointestinal stromal tumors and other mesenchymal lesions of the gut. Mod Pathol; 2003 Apr;16(4):366-75
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Along with this understanding comes an exciting new drug therapy (Gleevec) that for the first time offers real hope to patients with malignant stromal tumors.
  • Overall, approximately 60-70% of stromal tumors are from the stomach, 20-30% are from the small intestine, and <10% come from the esophagus, colon, rectum, omentum, and mesentery.
  • Although the most important tool needed to diagnose a GIST is still a hematoxylin and eosin-stained section, a confirmatory CD117 stain is recommended (and may be required for drug therapy).
  • True smooth muscle tumors, inflammatory fibroid polyps, fibromatoses, schwannomas, inflammatory myofibroblastic tumors, and solitary fibrous tumors all enter into the differential diagnosis of GISTs.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Benzamides. Diagnosis, Differential. Imatinib Mesylate. Immunohistochemistry. Molecular Biology. Piperazines / therapeutic use. Prognosis. Pyrimidines / therapeutic use

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12692202.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Biomarkers, Tumor; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  • [Number-of-references] 55
  •  go-up   go-down


8. Sokolova GN, Tsaregorodtseva TM, Zotina MM: [Changes in local humoral immunity during stomach ulcer healing with laser and drug therapy]. Eksp Klin Gastroenterol; 2002;(2):58-61, 103
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Changes in local humoral immunity during stomach ulcer healing with laser and drug therapy].
  • At the same time the level of SIgA decreased in comparison with unaltered gastric mucosa.
  • It is shown that the immunoglobulin content in the healed ulcer cicatrice depended on treatment method.
  • The medicamentous therapy was accompanied by lowering of the contents of IgG, IgA, SIgA and by some increase of IgM level.
  • The laser therapy is characterized by lowering of IgA, IgG, IgM level on a background of significant increase of SIgA content.
  • The local humoral immunity after laser therapy was the same as in persons with unaltered gastric mucosa.
  • [MeSH-major] Stomach / immunology. Stomach Ulcer / immunology. Stomach Ulcer / therapy
  • [MeSH-minor] Adult. Aged. Antacids / therapeutic use. Anti-Ulcer Agents / therapeutic use. Antibody Formation. Combined Modality Therapy. Gastric Mucosa / immunology. Gastric Mucosa / pathology. Histamine H2 Antagonists / therapeutic use. Humans. Immunoglobulin A / analysis. Immunoglobulin G / analysis. Immunoglobulin M / analysis. Low-Level Light Therapy. Middle Aged. Organometallic Compounds / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12046389.001).
  • [ISSN] 1682-8658
  • [Journal-full-title] Ėksperimental'nai︠a︡ i klinicheskai︠a︡ gastroėnterologii︠a︡ = Experimental & clinical gastroenterology
  • [ISO-abbreviation] Eksp Klin Gastroenterol
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia
  • [Chemical-registry-number] 0 / Antacids; 0 / Anti-Ulcer Agents; 0 / Histamine H2 Antagonists; 0 / Immunoglobulin A; 0 / Immunoglobulin G; 0 / Immunoglobulin M; 0 / Organometallic Compounds; HS813P8QPX / bismuth tripotassium dicitrate
  •  go-up   go-down


9. Toffoli G, Cecchin E: Clinical implications of genetic polymorphisms on stomach cancer drug therapy. Pharmacogenomics J; 2007 Apr;7(2):76-80
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical implications of genetic polymorphisms on stomach cancer drug therapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Patient Selection. Polymorphism, Single Nucleotide. Stomach Neoplasms / drug therapy. Stomach Neoplasms / genetics
  • [MeSH-minor] Biotransformation / genetics. Fluorouracil / therapeutic use. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Genotype. Humans. Treatment Outcome


10. Nikfarjam M, Kimchi E, Shereef S, Gusani NJ, Jiang Y, Liang J, Sehmbey M, Staveley-O'Carroll KF: Surgical outcomes of patients with gastrointestinal stromal tumors in the era of targeted drug therapy. J Gastrointest Surg; 2008 Nov;12(11):2023-31
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical outcomes of patients with gastrointestinal stromal tumors in the era of targeted drug therapy.
  • BACKGROUND: The discovery of the c-KIT mutation and the advent of targeted drug therapy with imatinib mesylate have revolutionized the management of gastrointestinal stromal tumors (GISTs).
  • The outcome of patients with surgically treated GISTs treated in the era of targeted drug therapy was assessed and factors associated with adverse outcomes determined.
  • The stomach (55%) was the main site of primary disease.
  • High mitotic rate (P = 0.017) and tumor size greater than 10 cm (P = 0.009) were the only prognostically significant adverse factors of DFS on multivariate analysis, independent of imatinib mesylate treatment.
  • CONCLUSION: Aggressive surgical treatment and follow-up of GISTs, combined with targeted drug therapy, leads to long-term DFS survival.
  • Tumor recurrence is independently associated with a high tumor mitotic rate and size greater than 10 cm, despite the use of adjuvant targeted drug therapy.
  • [MeSH-major] Gastrointestinal Stromal Tumors / drug therapy. Gastrointestinal Stromal Tumors / surgery. Piperazines / administration & dosage. Proto-Oncogene Proteins c-kit / drug effects. Pyrimidines / administration & dosage
  • [MeSH-minor] Aged. Benzamides. Chemotherapy, Adjuvant. Cohort Studies. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Delivery Systems. Female. Follow-Up Studies. Humans. Imatinib Mesylate. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Probability. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Statistics, Nonparametric. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2000 Jan;231(1):51-8 [10636102.001]
  • [Cites] Ann Surg Oncol. 2001 Jan-Feb;8(1):50-9 [11206225.001]
  • [Cites] J Clin Oncol. 2007 Mar 20;25(9):1107-13 [17369574.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Gastroenterology. 2005 Feb;128(2):270-9 [15685537.001]
  • [Cites] Arch Surg. 2001 Apr;136(4):383-9 [11296107.001]
  • [Cites] Ann Surg Oncol. 2008 Jan;15(1):52-9 [18000711.001]
  • [Cites] Hum Pathol. 2002 May;33(5):466-77 [12094371.001]
  • [Cites] Br J Cancer. 2007 Jun 4;96(11):1656-8 [17533389.001]
  • [Cites] Am J Surg Pathol. 1983 Sep;7(6):507-19 [6625048.001]
  • [Cites] Cancer. 1992 Feb 15;69(4):947-55 [1735086.001]
  • [Cites] J Clin Oncol. 2004 Sep 15;22(18):3813-25 [15365079.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] Ann Surg Oncol. 2007 Jan;14(1):134-42 [17080234.001]
  • [Cites] Lancet. 2004 Sep 25-Oct 1;364(9440):1127-34 [15451219.001]
  • [Cites] Mol Cancer Ther. 2005 Mar;4(3):495-501 [15767559.001]
  • [Cites] Curr Oncol Rep. 2005 Jul;7(4):293-9 [15946589.001]
  • [Cites] Ann Surg Oncol. 2007 Jan;14(1):14-24 [17072676.001]
  • [Cites] Cancer. 1992 Mar 15;69(6):1334-41 [1540870.001]
  • [Cites] Ann Surg. 2006 Jun;243(6):738-45; discussion 745-7 [16772777.001]
  • [Cites] Int J Cancer. 2005 Nov 1;117(2):289-93 [15900576.001]
  • [Cites] N Engl J Med. 2002 Feb 28;346(9):683-93 [11870247.001]
  • [Cites] J Clin Oncol. 2006 May 20;24(15):2325-31 [16710031.001]
  • [Cites] J Gastrointest Surg. 2007 Jan;11(1):114-25 [17390197.001]
  • [Cites] Br J Surg. 2006 Jul;93(7):836-43 [16705644.001]
  • [Cites] Semin Diagn Pathol. 2006 May;23(2):70-83 [17193820.001]
  • [Cites] Ann Surg. 2006 Aug;244(2):176-84 [16858179.001]
  • [Cites] Ann Oncol. 2005 Apr;16(4):566-78 [15781488.001]
  • [Cites] Cancer. 2005 Feb 15;103(4):821-9 [15648083.001]
  • [Cites] Br J Surg. 2003 Mar;90(3):332-9 [12594669.001]
  • [Cites] Am J Surg Pathol. 1999 Jan;23(1):82-7 [9888707.001]
  • [Cites] Lancet. 2006 Oct 14;368(9544):1329-38 [17046465.001]
  • [Cites] Lancet. 2007 May 19;369(9574):1731-41 [17512858.001]
  • [Cites] Ann Surg. 2007 Mar;245(3):347-52 [17435539.001]
  • [Cites] Ann Surg Oncol. 2007 Jul;14(7):2018-27 [17473953.001]
  • [Cites] Ann Surg. 1992 Jan;215(1):68-77 [1731651.001]
  • [Cites] Cancer Invest. 2005;23(3):274-80 [15945512.001]
  • [Cites] Cancer. 1982 Jan 1;49(1):177-87 [7053814.001]
  • [Cites] Curr Opin Oncol. 2005 Jul;17(4):361-5 [15933469.001]
  • (PMID = 18546049.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


11. Walter-Sack I, Haefeli WE: [Consideration of drug absorption in customizing drug therapy]. Ther Umsch; 2000 Sep;57(9):557-62

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Consideration of drug absorption in customizing drug therapy].
  • [Transliterated title] Berücksichtigung der Arzneimittelabsorption in der Individualisierung der Arzneimitteltherapie.
  • The rate and extent of drug absorption from the small intestine are related to the release of the active ingredient from a dosage form, its solubility in the liquid phase of gastrointestinal contents, and the transport of the dissolved compound or the intact dosage form from the stomach into the duodenum.
  • With pharmaceutical preparations releasing the active compound within the stomach, and enteric-coated "micro"-formulations (micropellets), gastric emptying is possible during the interdigestive and the digestive period.
  • Potential differences of drug absorption between fasting administration and intake during the digestive period are unpredictable, because they are related to the release characteristics of the dosage form.
  • However, larger enteric-coated preparations like tablets can leave the stomach only with a phase 3 contraction of fasting motility; intake during the digestive period will result in gastric retention of this type of dosage form until all food has left the stomach and fasting motility is restored.
  • Consequently the onset of drug absorption is delayed.
  • If concomitant intake of food and enteric-coated drugs is unavoidable, but a rapid onset of drug absorption is necessary, micropellets are the dosage form of choice.
  • When the therapeutic effect is insufficient, drug dosage form and timing of drug administration should be checked before prescribing a different active compound.
  • [MeSH-major] Dosage Forms. Drug Prescriptions. Pharmacokinetics
  • [MeSH-minor] Biological Availability. Drug Administration Schedule. Humans. Patient Care Planning

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11036435.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] SWITZERLAND
  • [Chemical-registry-number] 0 / Dosage Forms
  • [Number-of-references] 26
  •  go-up   go-down


12. Devière J: Do selective cyclo-oxygenase inhibitors eliminate the adverse events associated with nonsteroidal anti-inflammatory drug therapy? Eur J Gastroenterol Hepatol; 2002 Sep;14 Suppl 1:S29-33
Hazardous Substances Data Bank. Meloxicam .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do selective cyclo-oxygenase inhibitors eliminate the adverse events associated with nonsteroidal anti-inflammatory drug therapy?
  • Among the most widely prescribed drugs worldwide, non-steroidal anti-inflammatory drugs (NSAIDs) are effective for relieving pain, but they are also associated with a high incidence of gastrointestinal (GI) adverse events.
  • Recognition of the two distinct COX isoforms prompted development of drugs that selectively block the activity of COX-2, thus providing pain relief and reducing inflammation while sparing COX-1, the enzyme apparently responsible for most protective prostaglandin synthesis in the mucosa of the stomach and duodenum.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / adverse effects. Cyclooxygenase Inhibitors / therapeutic use
  • [MeSH-minor] Alzheimer Disease / drug therapy. Celecoxib. Humans. Lactones / therapeutic use. Neoplasms / drug therapy. Pyrazoles. Sulfonamides / therapeutic use. Sulfones. Thiazines / therapeutic use. Thiazoles / therapeutic use

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CELECOXIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12570027.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Cyclooxygenase Inhibitors; 0 / Lactones; 0 / Pyrazoles; 0 / Sulfonamides; 0 / Sulfones; 0 / Thiazines; 0 / Thiazoles; 0QTW8Z7MCR / rofecoxib; 71125-38-7 / meloxicam; JCX84Q7J1L / Celecoxib; V4TKW1454M / nimesulide
  • [Number-of-references] 41
  •  go-up   go-down


13. Iakovenko AV, Grigor'ev PIa, Iakovenko EP, Agafonova NA, Prianishnikova AS, Ivanov AN, Aldiiarova MA, Soluianova IP, Anashkin VA, Oprishchenko IV: [Cytoprotectors in stomach diseases therapy. Best practice in the drug selection]. Eksp Klin Gastroenterol; 2006;(2):56-9
MedlinePlus Health Information. consumer health - Stomach Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cytoprotectors in stomach diseases therapy. Best practice in the drug selection].
  • [MeSH-major] Cytoprotection. Protective Agents / therapeutic use. Stomach Diseases / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16866267.001).
  • [ISSN] 1682-8658
  • [Journal-full-title] Ėksperimental'nai︠a︡ i klinicheskai︠a︡ gastroėnterologii︠a︡ = Experimental & clinical gastroenterology
  • [ISO-abbreviation] Eksp Klin Gastroenterol
  • [Language] rus
  • [Publication-type] Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Protective Agents
  • [Number-of-references] 8
  •  go-up   go-down


14. Sazhin VP, Fedorov AV: [Current principles of the use of laparoscopic surgery in gastroduodenal ulcer]. Khirurgiia (Mosk); 2001;(6):12-7
Hazardous Substances Data Bank. Clarithromycin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Comparative assessment of treatment results in 618 patients with gastroduodenal ulcer (GDU) was carried out.
  • Different combinations of drugs were used in 384 patients, 234 patients have undergone open resections of the stomach or organsaving operations, 83 patients--analogous laparoscopic operations.
  • Immediate and long-term results of the treatment were studied.
  • After drug therapy, including antihelicobacter drugs, healing of ulcers was achieved in 96.9-97.9% cases.
  • 1 year after drug therapy the recurrence of CDU is revealed in 16.2-20.3% patients, rate of the recurrence increases with years.
  • After surgical treatment of CDU (more often in complicated course of the disease) rate of recurrences is 2-3 times lower (6.5-7.4% cases).
  • Laparoscopic resections of the stomach and organsaving operations are atraumatic, accompanied by physiologic course of postoperative period and reduction of postoperative complication rate.
  • [MeSH-minor] Antacids / administration & dosage. Antacids / therapeutic use. Anti-Bacterial Agents / administration & dosage. Anti-Bacterial Agents / therapeutic use. Anti-Ulcer Agents / administration & dosage. Anti-Ulcer Agents / therapeutic use. Clarithromycin / administration & dosage. Clarithromycin / therapeutic use. Drug Therapy, Combination. Duodenal Ulcer / surgery. Follow-Up Studies. Gastrectomy. Helicobacter Infections / drug therapy. Helicobacter pylori. Humans. Metronidazole / administration & dosage. Metronidazole / therapeutic use. Omeprazole / administration & dosage. Omeprazole / therapeutic use. Organometallic Compounds / administration & dosage. Organometallic Compounds / therapeutic use. Postoperative Complications. Ranitidine / administration & dosage. Ranitidine / therapeutic use. Recurrence. Stomach Ulcer / surgery. Tetracycline / administration & dosage. Tetracycline / therapeutic use. Time Factors

  • MedlinePlus Health Information. consumer health - Peptic Ulcer.
  • Hazardous Substances Data Bank. METRONIDAZOLE .
  • Hazardous Substances Data Bank. TETRACYCLINE .
  • Hazardous Substances Data Bank. RANITIDINE .
  • Hazardous Substances Data Bank. OMEPRAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11517693.001).
  • [ISSN] 0023-1207
  • [Journal-full-title] Khirurgiia
  • [ISO-abbreviation] Khirurgiia (Mosk)
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia
  • [Chemical-registry-number] 0 / Antacids; 0 / Anti-Bacterial Agents; 0 / Anti-Ulcer Agents; 0 / Organometallic Compounds; 140QMO216E / Metronidazole; 884KT10YB7 / Ranitidine; F8VB5M810T / Tetracycline; H1250JIK0A / Clarithromycin; HS813P8QPX / bismuth tripotassium dicitrate; KG60484QX9 / Omeprazole
  •  go-up   go-down


15. Tisman G, Kutik SJ, Khan YA: Chemotherapy-induced suppression of serum holotranscobalamin. J Clin Oncol; 2009 May 20;27(15_suppl):e20639

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy-induced suppression of serum holotranscobalamin.
  • : e20639 Purpose: Chemotherapy-induced damage to the stomach and small intestine may inhibit the absorption of vitamin B12.
  • To assess the risk of chemotherapy causing acute vitamin B12 deficiency, we primarily measured the active form of vitamin B12, holotranscobalamin, but also total serum B12, methylmalonic acid, and total homocysteine.
  • EXPERIMENTAL DESIGN: We studied 21 patients that were actively on chemotherapy and recorded values for holotranscobalamin, total serum B12, methylmalonic acid, total homocysteine, and cystatin-c.
  • Measurements were taken both before and after four doses of chemotherapy.
  • RESULTS: There was a statistically significant drop in holotranscobalamin after chemotherapy in eighteen out of twenty-one patients (p = 2.64x10-3).
  • CONCLUSIONS: Chemotherapy caused an acute deficiency of the only metabolically active form of vitamin B12, holotranscobalamin, despite B12 supplementation.
  • The clinical implications of acute lowering of holotranscobalamin remain unknown.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961573.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Park YH, Ryoo BY, Choi SJ, Kim HT: Paclitaxel plus cisplatin in cancer of unknown primary site (CUP). J Clin Oncol; 2004 Jul 15;22(14_suppl):2123

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel plus cisplatin in cancer of unknown primary site (CUP).
  • : 2123 Cancer of unknown primary site (CUP) consists of a heterogeneous group of tumors that have acquired the capacity to metastasize before the development of a clinically evident primary lesion.
  • This study was designed to evaluate the efficacy and toxicity of paclitaxel / cisplatin combination chemotherapy in patients with CUP.
  • The rationale for choosing this combination is based on available clinical data that paclitaxel and cisplatin have shown considerable clinical activity in various common malignant tumors including lung, breast, stomach, esophagus, ovary and head/neck cancer.
  • The patients received a total of 138 cycles of chemotherapy.
  • The median number of cycles of chemotherapy per patient was 4.
  • Median time to progression was 4 (95% C.I., 1.3-6.8) months.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28017099.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Scott LC, Evans T, Yao JC, Benson AI, Mulcahy M, Thomas A, Decatris M, Falk S, Rudoltz M, Ajani JA: Pegamotecan (EZ-246), a novel PEGylated camptothecin conjugate, for treatment of adenocarcinomas of the stomach and gastroesophageal (GE) junction: Preliminary results of a single-agent phase 2 study. J Clin Oncol; 2004 Jul 15;22(14_suppl):4030

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pegamotecan (EZ-246), a novel PEGylated camptothecin conjugate, for treatment of adenocarcinomas of the stomach and gastroesophageal (GE) junction: Preliminary results of a single-agent phase 2 study.
  • <sup>1</sup> This phase 2 study was designed to evaluate the activity of pegamotecan in advanced and metastatic adenocarcinomas of the stomach and GE junction.
  • Eligibility criteria included: pathologically confirmed measurable adenocarcinoma of the stomach or GE junction, performance status 0-2, ≤ 1 prior chemotherapy regimens, no prior treatment with a camptothecin analog.
  • Two subjects developed grade 2 cystitis, in each of whom dehydration was reported.
  • CONCLUSIONS: Pegamotecan is a promising treatment for adenocarcinoma of the stomach and GE junction.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014388.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Burzykowski T, Bang Y, GASTRIC project: Disease-free survival as a surrogate endpoint for overall survival in an adjuvant trial of curatively resected stomach cancer using individual patient data meta-analysis. J Clin Oncol; 2009 May 20;27(15_suppl):4517

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disease-free survival as a surrogate endpoint for overall survival in an adjuvant trial of curatively resected stomach cancer using individual patient data meta-analysis.
  • : 4517 Background: In investigations of the effectiveness of oncology drugs, overall survival (OS) is considered as the gold standard end point.
  • DFS is defined as recurrence of stomach cancer, all second cancers, or death from any cause.
  • We evaluated 3 year DFS as a surrogate for 5 year OS in adjuvant trials of stomach cancer by using individual-patient data (IPD) meta- analysis validation criteria.
  • METHODS: The GASTRIC group initiated an IPD meta-analysis of all randomized clinical trials comparing chemotherapy versus surgery alone for patients with curatively resected stomach cancer.
  • The validity of DFS at 3 years as a surrogate for OS at 5 years was investigated by using multiple analysis techniques, which included measures of correlation between the endpoints and between the treatment effects, and the percentage of agreement in the log-rank tests for the two endpoints at the trial level.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962696.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Pozzo C, Ohashi Y, GASTRIC project: Meta-analyses of randomized trials assessing the influence of chemotherapy and prognostic factor in advanced/recurrent gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):4550

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meta-analyses of randomized trials assessing the influence of chemotherapy and prognostic factor in advanced/recurrent gastric cancer.
  • : 4550 Background: Advanced or recurrent stomach cancer remains an incurable disease.
  • Several drugs and different combinations of chemotherapy have been investigated but very often with small sample sizes making definitive conclusions difficult.
  • We used this large database to study the role of various prognostic factors and potential interactions with chemotherapy.
  • Radiotherapy, intraperitoneal chemotherapy, or immunotherapy was excluded.
  • In the multivariate Cox regression analysis stratified by trial and treatment arm, PS of 2 (HR, 2.43; 95%CI, 2.02 to 2.94) compared to PS of 0, metastatic (HR, 1.29; 95%CI, 1.01 to 1.64) compared to local advanced, many number of organs, and location of metastasis (especially with peritorium; HR, 1.75; 95%CI, 1.23 to 2.48) compared to none were strongly associated with lower survival.
  • CONCLUSIONS: Our interim results could not show an overall survival benefit in favour of 5FU-, anthracycline-, platinum-, taxane-, or irinotecan-based regimens compared with a regimen without the specific chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963035.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Hohenberger P, Oladeji O, Licht T, Dimitrakopoulou-Strauss A, Jakob J, Pink D, Schwarzbach M, Ströbel P, Reichardt P, Wardelmann E: Neoadjuvant imatinib and organ preservation in locally advanced gastrointestinal stromal tumors (GIST). J Clin Oncol; 2009 May 20;27(15_suppl):10550

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 10550 Background: We assessed the outcome of patients with locally advanced gastrointestinal stromal tumors (GIST) undergoing preoperative therapy with imatinib.
  • METHODS: 36 patients with biopsy proven GIST (23 f, 13 m, median age 58 (27-85) yrs, 31 primary tumors, 5 local recurrences) of the esophagus/EGJ (n=5), stomach (n=17), duodenum (n=2), small bowel (n=3), or rectum (n=9) were treated with imatinib 400mg/d for 6 mos. preop.
  • According to Consensus two tumors were low risk, 11 intermediate, and 23 were high risk for aggressive behaviour.
  • Extent of surgery, local outcome, morbidity and response to therapy were analyzed; median follow-up is 22 mos.
  • RESULTS: Median treatment duration was 11 mos. (range 2-31 mos).
  • 33 pts. completed the treatment schedule, two died from unrelated disease, another one had to be operated for tumor rupture.
  • Two elderly patients refused surgery and continued with the drug; one pt. was found still unresectable.
  • The extent of resection found 5 of 6 inoperable pts now resectable and in 21/25 pts a less extensive procedure could be performed in comparison to recommendations by previous tumor boards (segmental gastric resection for gastrectomy, avoidance of pancreatectomy, transanal resection instead of colo-anal anastomosis).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963946.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Schuhmacher C, Schlag P, Lordick F, Hohenberger W, Heise J, Haag C, Gretschel S, Mauer ME, Lutz M, Siewert JR: Neoadjuvant chemotherapy versus surgery alone for locally advanced adenocarcinoma of the stomach and cardia: Randomized EORTC phase III trial #40954. J Clin Oncol; 2009 May 20;27(15_suppl):4510

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy versus surgery alone for locally advanced adenocarcinoma of the stomach and cardia: Randomized EORTC phase III trial #40954.
  • : 4510 Background: Combined pre- and postoperative chemotherapy improves overall survival in operable gastric cancer, although postoperative treatment is not feasible in half of the patients.
  • We conducted a randomized phase III trial with thorough attention to preoperative staging and to the extent of surgical resection to assess the value of neoadjuvant chemotherapy (CTx).
  • METHODS: Patients with locally advanced adenocarcinoma of the stomach and cardia were randomized between primary surgery or two 48-day cycles of weekly folinic acid 500 mg/m<sup>2</sup>/2h, 5-FU 2,000 mg/m<sup>2</sup>/24h plus biweekly cisplatin 50 mg/m<sup>2</sup>/1h followed by surgery.
  • The study was designed to detect an improvement in median survival from 17 months with surgery to 24 months with CTx plus surgery (HR=0.708, power of 80%, type I error of 4% to allow for an interim analysis).
  • Based on 77 events, difference in time to progression was borderline significant (HR=0.66; 95% CI, 0.42-1.03; p=0.065).
  • The outcome after a radical surgical procedure alone with extended lymphadenectomy was better than expected.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962708.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Madiajagane R: Adenocarcinoma of stomach-epidemiology and treatment results of rural South Indian experience. J Clin Oncol; 2004 Jul 15;22(14_suppl):4172

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of stomach-epidemiology and treatment results of rural South Indian experience.
  • : 4172 Background: Adenocarcinoma of stomach is one of the common problems in India.
  • Most often this is diagnosed in locoregionally advanced or in Metastatic stage.Chemotherapy is needed in most cases of ca Stomach .This study deals with adenocarcinoma of stomach in the rural south Indian population.This is a retrospective analysis.
  • METHODS: The diagnosis was by endoscopic biopsy.
  • Non Metastatic ca stomach was treated with initial surgery.Chemotherapy was offered to those with Metastatic,node positive or seosa or muscle positive patients The common chemotherapy protocol used was ELF (Etoposide 100 mg/m2,Leucovorin 30mg/m2,5FU 350 mg/m2 all IVF d1-d3) at three weekly interval for six cycles.
  • RESULTS: Total of eighty patients were analysed.The lesion was in70% distal, 17% proximal and 13% unknown site.
  • 29 patients had adjuvant and 51 had palliative chemotherapy.
  • 59%in adjuvant and 29%in palliation were regular for treatment.31% relapsed in adjuvant group.In the palliative group56%had stable disease and 44%had progressive disease.The follow up in adjuvant group was 1-155Wks(mean 36 and median 28)and in the palliative group 1 - 52 wks(mean 11 and median 5 wks).Toxicity is grade 1 or 2 and there was no toxic death.
  • CONCLUSION: Chemotherapy is needed for most of these patients of ca stomach.
  • ELF protocol was simple and relatively non toxic protocol.Inspite of this a fair proportion in both adjuvant and palliative groups were not regular on treatment.
  • Apart from addressing superior chemotherapy, we also need to investigate areas to improve patient compliance, nutritional complications of gastrectomy and quality symptom management like standard gastric diversion procedure.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013750.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Steinert DM, Blakely LJ, Patel SR, Burgess MA, Chen LL, Trent JC, Raymond AK, Benjamin RS: Outcomes of gastrointestinal stromal tumors (GIST) and other intra-abdominal sarcomas (IAS) in the era of imatinib therapy. J Clin Oncol; 2004 Jul 15;22(14_suppl):9047

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of gastrointestinal stromal tumors (GIST) and other intra-abdominal sarcomas (IAS) in the era of imatinib therapy.
  • In the era of kit immunohistochemistry and imatinib mesylate therapy the outcome of IASs is unknown.
  • METHODS: We analyzed 268 consecutive patients who were referred to our institution for evaluation of the diagnosis of GIST from 12/15/00 to 9/1/01.
  • Patients diagnosed with GIST were treated with imatinib mesylate, and patients diagnosed with other IAS were treated with standard sarcoma chemotherapy.
  • Another 46 patients were excluded because no data were available at the time of this abstract.
  • Of the remaining 218 patients, 159 (72.9%) were GIST and 59 (27.1%) were IAS specifically: 31 leiomyosarcoma, 10 spindle cell tumors, 4 unclassified sarcomas, and 14 other types of sarcoma.
  • The most common primary tumor sites for patients with GIST were stomach (37.1%), small bowel (34%), and colon (6.3%); whereas, patients with other intra-abdominal sarcomas occurred in the retroperitoneum (25.4%), abdominal viscera (18.6%), and pelvis (11.9%).
  • While median survival from the time of diagnosis has not been reached in patients with GIST, in other IAS median survival is 63.8 months.
  • Time to progression in patients with GIST was 16.4 months after imatinib and 5.1 months in patients with IAS treated with standard sarcoma chemotherapy.
  • CONCLUSIONS: Survival and time to progression are worse for IAS compared to GISTs.
  • New therapies for these tumors are needed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014121.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Maring JG, Oonk BN, De Vries EG, Hospers GA: Plasma pharmacokinetics of uracil after an oral uracil challenge dose for dihydropyrimidine dehydrogenase (DPD) phenotyping. J Clin Oncol; 2004 Jul 15;22(14_suppl):2120

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In patients with DPD enzyme deficiency, 5-FU chemotherapy is associated with severe, life-threatening toxicity.
  • The volunteers ingested 500 mg/m<sup>2</sup> uracil as an oral solution on an empty stomach.
  • The oral Uracil Challenge Test is currently investigated in previously characterized, partially DPD deficient patients to determine its use in pre-chemotherapy DPD-phenotyping.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28017101.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Awada A, Clark R, Dumez H, Gil T, Hanauske A, Piccart M, Suri A, Van Oosterom A: Phase I trial of pemetrexed plus paclitaxel administered every 21 days in patients with advanced solid tumors. J Clin Oncol; 2004 Jul 15;22(14_suppl):2053

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Post VS amendment, 12 pts [8 M, 4 F; median age 49; prior chemotherapy (11 pts)] were enrolled at 500/135.
  • No dose reductions, omissions, or drug-related deaths reported.
  • Stable disease reported in 5 pts: head/neck (2), mesothelioma (2), stomach (1).
  • There was no significant change in exposure of either drug when given concomitantly.
  • In a phase 2 study of this combination, pts should have vitamin supplementation, good PS and bone marrow reserve, and minimal prior chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015660.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Kanzler S, Trarbach T, Seufferlein T, Kubicka S, Lordick F, Geissler M, Daum S, Galle PR, Moehler M, German Arbeitsgemeinschaft Internistische Onkologie (AIO): Cetuximab with irinotecan/folinic acid/5-FU as first-line treatment in advanced gastric cancer: A nonrandomized multicenter AIO phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):4534

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cetuximab with irinotecan/folinic acid/5-FU as first-line treatment in advanced gastric cancer: A nonrandomized multicenter AIO phase II study.
  • : 4534 Background: Cetuximab has demonstrated high efficacy in combination with irinotecan-based therapies in metastatic colorectal cancer and irinotecan/folinic acid/5-FU (IF) may be an effective alternative to cisplatin-based regimens in advanced gastric cancer.
  • We therefore conducted a phase II AIO study to evaluate the tolerability and efficacy of cetuximab combined with IF as first-line treatment in patients with advanced gastric cancer.
  • METHODS: Patients (pts) were eligible with untreated adenocarcinoma of the stomach or oesophagogastric junction, with ECOG performance status (PS) < 2, measurable lesions and adequate organ functions.
  • Pts received weekly cetuximab (first dose 400 mg/m<sup>2</sup>, subsequent doses 250 mg/m<sup>2</sup>) combined with chemotherapy consisting of irinotecan (80 mg/m<sup>2</sup>) plus 24 hours continuous infusion of sodium folinic acid (Na-FA: 200 mg/m<sup>2</sup>) and 5-FU (1500 mg/m<sup>2</sup>) on days 1, 8, 15, 22, 29 and 36 of a 50-day cycle.
  • Treatment was continued until tumor progression and tumor assessments were performed every 2nd cycle.
  • The median treatment time was 15.2 weeks (range 1.1-69.1).
  • Median progression-free and overall survival times were 8.5 months (36.6 weeks; 95% CI 30.1; 48.1) and 16.6 months (71.1 weeks; 95% CI 50; 93.4), respectively.
  • Cetuximab combined with chemotherapy in advanced or metastatic gastric cancer is under further investigation in an ongoing phase III trial.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962992.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Bose P, Thompson CL, Gandhi DG, Ghabach BS, Ozer H: Response of AIDS-related plasmablastic lymphoma (PBL) to bortezomib. J Clin Oncol; 2009 May 20;27(15_suppl):e19562

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EGD with biopsy revealed a high-grade PBL of the stomach.
  • The diagnosis was stage IVBE PBL.
  • Highly active anti-retroviral therapy was begun.
  • Anthracycline-based chemotherapy was avoided due to persistent hyperbilirubinemia.
  • PET/CT on day 7 showed a marked decrease in hypermetabolism after only 2 doses, signifying a dramatic treatment response.
  • We chose bortezomib based on our patient's poor performance status and immune function, the desire to avoid combination chemotherapy, and translocations involving the immunoglobulin heavy chain gene locus (8;14) similar to those seen in multiple myeloma(4;14, 14;16) and mantle cell lymphoma(11;14).
  • A shift in the paradigm of treatment of PBL towards agents effective in plasma cell malignancies may be necessary.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961065.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Hoque E, Karim S, Hossen M, Ahmed TU: Study to see the efficacy and toxicity profile of docetaxel-based chemotherapy in advanced stomach cancer in Bangladeshi patient population. J Clin Oncol; 2009 May 20;27(15_suppl):e15687

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Study to see the efficacy and toxicity profile of docetaxel-based chemotherapy in advanced stomach cancer in Bangladeshi patient population.
  • The purpose of this study was to investigate the efficacy and toxicity profile of docetaxel based chemotherapy in advanced stomach cancer in Bangladeshi patient population.
  • Patients received no prior chemotherapy.
  • The primary end point was time to tumour progression.
  • RESULTS: Among the 30 evaluable patients time to tumour progression was 11.5 months.
  • Complete response rate was 20% (6 patients), 27% (8 patients) had stable disease, 7% (2 patients) had developed progressive disease.
  • Grade 3 to 4 treatment related adverse events occurred in 63%.
  • There was no treatment related death.
  • CONCLUSIONS: Adding docetaxel to CF regimen significantly improved time to tumour progression and survival rate in advanced gastric cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962798.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Chatterjee A, Bhattacharya S, Chatterjee AK, Biswas J, Mukhopadhyay B: A prospective observational clinical study involving an alternative cancer treatment, psorinum therapy, in treating stomach, gallbladder, pancreas, and liver cancers. J Clin Oncol; 2009 May 20;27(15_suppl):3050

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective observational clinical study involving an alternative cancer treatment, psorinum therapy, in treating stomach, gallbladder, pancreas, and liver cancers.
  • : 3050 Background: The prospective observational clinical study was conducted to know the efficacy of an alternative cancer treatment, 'psorinum therapy,' in treating liver, gall bladder, pancreatic, and stomach cancers.
  • The secondary outcome measure of the study was to assess the side effects of the investigational anti-cancer drug (psorinum) if any.
  • METHODS: The drug psorinum (an alcoholic extract of scabies, scrub, slough, and pus cells) was administered orally at 0.01ml-0.02 ml/Kg body weight as a single dose in empty stomach per day and ongoing to all the participants along with allopathic and homeopathic supportive cares.
  • RESULTS: 158 histopathology or cytopathology proved participants (42 of stomach, 40 of gallbladder, 44 of pancreas, and 32 of liver cancers) were included in the final analysis at the end of the study.
  • These participants did not receive any other conventional or investigational cancer treatments.
  • The participants report no side effects from the drug psorinum.
  • CONCLUSIONS: Psorinum therapy is effective in treating stomach, gallbladder, pancreas, and liver cancers.
  • Double-blinded randomized controlled clinical trial should be done for further investigation of this alternative cancer treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961982.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Bokemeyer C, Kollmannsberger C, Budach W, Stahl M, Schleucher N, Hehr T, Wilke HJ, Vanhoefer U, Schleicher J, Kanz L: Adjuvant radiochemotherapy (RTx/CTx) using 5-FU/Folinic acid (FA) /cisplatin (DDP) ± paclitaxel (P) and radiation in patients (pts) with completely (R0) resected high-risk gastric cancer (UICC stages II-IV (M0): An extended phase II study of the AIO/ARO/ACO. J Clin Oncol; 2004 Jul 15;22(14_suppl):4036

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The current study evaluates the feasibility, toxicity and efficacy of a novel adjuvant combined modality treatment strategy containing a 3-4-drug chemotherapy regimen (CTx) plus 5-FU-based RTx/CTx.
  • Treatment consisted of 2 cycles of FA 500 mg/m<sup>2</sup> (2h) / 5-FU 2000 mg/m<sup>2</sup> (24h) once weekly for 6 consecutive weeks, P 175 mg/m<sup>2</sup> (3h) weeks 1 and 4 and DDP 50 mg/m<sup>2</sup> (1h) weeks 2 and 5 or 2 cycles of FA 500 mg/m<sup>2</sup> (2h) / 5-FU 2000 mg/m<sup>2</sup> (24h) once weekly for 6 consecutive weeks with DDP 50 mg/m<sup>2</sup> (1h) weeks 1,3,5.
  • Radiation therapy with 45 Gy plus concomitantly applied 5-FU 225mg/m<sup>2</sup>/24h was scheduled in between the 2 cycles.
  • Pts with completely resected adenocarcinoma of the stomach including a systematic D1 or D2 lymph node dissection (LND) were eligible.
  • RESULTS: Treatment: FA/5-FU/P/DDP 44 pts; FA/5-FU/DDP 52 pts.
  • CONCLUSIONS: These novel RTx/CTx regimens appear feasible and safe with acceptable toxicity indicating that DDp can be safely added to 5-FU/FA and that even a 3-drug regimen is a feasible treatment option for adjuvant radiochemotherapy in gastric cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014393.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Moehler MH, Siebler J, Hoehler T, Janssen J, Wein A, Menges M, Flieger D, Junginger T, Galle PR, Heike M: CPT11/FA/5-FU versus ELF in chemonaive patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: A randomized phase II study. J Clin Oncol; 2004 Jul 15;22(14_suppl):4064

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CPT11/FA/5-FU versus ELF in chemonaive patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: A randomized phase II study.
  • METHODS: Metastatic or locally advanced adenocarcinoma of the stomach or gastroesophageal junction; performance status (PS) 0-2; no prior chemotherapy.
  • Median treatment duration were 14.1 (0.1-90) and 6.4 (0.3-61) weeks.
  • Median progression-free time for A/B: 129 (CI95% 8-693) and 63 (0-545) days.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014406.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Altinbas M, Kaplan B, Ucar K, Ozkan M, Karahacioglu E, Er O, Kucuk C, Soyuer I: 5-FU plus leucovorin (Mayo Regimen) for concurrent chemoradiotherapy after surgery in patients with resectable locally advanced gastric carcinoma: Preliminary results of a phase II study. J Clin Oncol; 2004 Jul 15;22(14_suppl):4196

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 4196 Background: Patients with locoregionally advanced carcinoma of the stomach have a grim outcome due to frequent local and systemic recurrences after surgery.
  • To potentially increase the local control or survival rate and decrease relapses, we investigated a strategy of concurrent chemoradiotherapy and followed by consolidation chemotherapy after surgery.
  • Adjuvant chemotherapy (250 mg/m2 5-FU) was administered concurrently on the first day of every radiotherapy weeks [which was totally standart field radiotherapy (RT), or total abdominal field RT up to 20 Gy first, then returned to standart field RT], .
  • After chemoradiotherapy regimen, consolidation chemotherapy consisted of 450 mg/mg 5-FU plus 20 mg/m2 Leucovorin was applied up to four cycles, q28 d.
  • Six patients in both arms did not get consolidation chemotherapy.
  • There were no deaths related to chemotherapy, chemoradiotherapy, or surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013890.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Jani J, Barbacci E, Bhattacharya S, Boos C, Campbell M, Clark T, Coleman K, Connell R, Cosker T, Pfizer HER2 Inhibitor Team: Discovery and development of CP-724714, a selective HER2 receptor tyrosine kinase inhibitor. J Clin Oncol; 2004 Jul 15;22(14_suppl):3122

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 3122 Background: The HER2 (neu/erbB2) proto-oncogene has been linked to human malignancies including tumors of the breast, ovary and stomach.
  • Amplification of the HER2 gene and over-expression of this membrane receptor tyrosine kinase has been implicated in tumor growth, sensitivity to standard chemotherapy, prognosis of patients and disease free survival.
  • Pre-clinical findings suggest that CP-724,714 is an orally bio-available compound with moderate clearance (11-12 ml/min/kg), and a low probability of drug:drug interactions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014873.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Bang Y, Chung H, Xu J, Lordick F, Sawaki A, Al-Sakaff N, Lipatov O, See C, Rueschoff J, Van Cutsem E: Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. J Clin Oncol; 2009 May 20;27(15_suppl):4556

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The ToGA trial is evaluating the addition of trastuzumab (Herceptin) to chemotherapy in HER2-positive advanced GC.
  • HER2-positivity rates were higher in gastro-oesophageal junction (GEJ) than stomach cancer (33.2% vs 20.9%; p<0.001) and in intestinal than diffuse/mixed cancer (32.2% vs 6.1%/20.4%; p<0.001).
  • This is reflected in above-average HER2-positivity rates in countries with the highest GEJ:stomach cancer ratios (France 0.56 [HER2 positivity 26.9%]; Germany 0.53 [23.7%]; UK 0.33 [25.8%]) and intestinal:diffuse cancer ratios (UK 3.4 [HER2 positivity 25.8%]; Australia 2.6 [32.8%]; Japan 2.8 [27.8%]).
  • Variations in tumour location and type mostly explain the difference in HER2-positivity rates between countries.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963029.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Lee H, Yuh Y, Kim S: Serum lactate dehydrogenase (LDH) level as a prognostic factor for the patients with advanced gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15621

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Moreover, the relationship between the change of serum LDH level after chemotherapy and the response to the treatment has not been studied, yet.
  • We analyzed serum LDH level as a prognostic factor for the patients with advanced stomach cancer.
  • METHODS: We assessed serum LDH level before chemotherapy for the patients who were planned to receive palliative chemotherapy.
  • We re-assessed their serum LDH level at the time when the response to chemotherapy was evaluated after 2-4 cycles of treatment.
  • The survival duration and the response to chemotherapy for the patients with low serum LDH level were compared to the survival duration and the response to chemotherapy for the patients with high serum LDH level.
  • The relationship between the change of serum LDH level and the response to the treatment was evaluated, too.
  • RESULTS: Total 118 patients were entered into this study and 114 patients were evaluable for their response to chemotherapy.
  • Pre-treatment serum LDH level was normal in 88 patients and elevated in 30 patients.
  • The normalizing of the elevated serum LDH level after chemotherapy was related to the good response to treatment (response rate 50.0% versus 18.8%, p < 0.05).
  • CONCLUSIONS: For the patients with advanced gastric cancer, high serum LDH level was related to better response to chemotherapy but shorter survival duration.
  • The normalization of elevated serum LDH level after chemotherapy was related to good response to treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962703.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Aguiar Bujanda D, Bohn Sarmiento U, Saura Grau S, Rodriguez Franco C, Aguiar Morales J: Clinical activity of rituximab with either CHOP or CVP in MALT lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):e19530

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rituximab has been proven to be an active agent in the treatment of MALT lymphoma.
  • Several reports suggest that the activity of rituximab can be improved when added to chemotherapy.
  • We aimed to evaluate safety and activity of rituximab combined with chemotherapy (CHOP or CVP) in first-line therapy for MALT lymphoma.
  • Patients with gastric MALT lymphoma were included if resistant to or not eligible for anti-Helicobacter pylori therapy.
  • Primary origin: 14 stomach (64%), 3 skin, and 5 others (nodal, parotid gland, orbital, colon, and lung).
  • The treatment was well tolerated with mild toxicity.
  • Patients with gastric lymphoma did not have bleeding or perforation during therapy.
  • None of the patients progressed during therapy.
  • Radiation therapy was given as consolidation after chemotherapy to 3 patients with extra-gastric origin.
  • CONCLUSIONS: Combination of rituximab with either CHOP or CVP is very active with acceptable toxicity in the treatment of MALT lymphoma.
  • Further studies are needed to elucidate the optimal combination of rituximab and chemotherapy in this patient population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961030.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Yoon J, Cho S, Bae W, Hwang J, Shim H, Chung I: Phase II study of irinotecan, 5-fluorouracil (5-FU) and leucovorin combination chemotherapy in taxane and cisplatin-based chemotherapy-refractory metastatic gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15599

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of irinotecan, 5-fluorouracil (5-FU) and leucovorin combination chemotherapy in taxane and cisplatin-based chemotherapy-refractory metastatic gastric cancer.
  • : e15599 Background: The role of the second line chemotherapy in advanced gastric cancer was not clear, but possibility of prolongation of survival is open question.
  • Irinotecan is promising agents in gastric cancer and this phase II study evaluated the efficacy and safety of combination chemotherapy with irinotecan, high dose of 5-fluorouracil (5-FU) and leucovorin in taxane and cisplatin based chemotherapy refractory metastatic gastric cancer.
  • METHODS: Eligible criteria were as followed; histologic confirmed adenocarcinoma of stomach, previously treated with taxane and cisplatin, age≥18, Eastern Clinical Oncology Group (ECOG) performance status of 1 or less, adequate organ function.
  • CONCLUSIONS: This results showed that the combination chemotherapy with irinotecan, 5-FU and leucovorin was well tolerated and active in taxane and cisplatin refractory patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962881.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Price V, Zielenska M, Smith C, Chilton-Macneill S, Malkin D, Pappo A: Clinical and molecular characteristics of pediatric gastrointestinal stromal tumors (GISTs). J Clin Oncol; 2004 Jul 15;22(14_suppl):8537

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The natural history and molecular characteristics of these tumors in children are virtually unknown.
  • OBJECTIVE: Describe clinical characteristics, treatment, outcome, and molecular features of pediatric GISTs.
  • Analysis of other coding sequences of the gene is being performed and will be presented at the meeting Results: The characteristics of the patients are depicted in the table.The median age at diagnosis was 13.6 years (range 6.9-14.8 years).Four patients were female.
  • The common primary site was the stomach.
  • All of the tumors were surgically resected and none of the pts received chemotherapy.
  • CONCLUSION: GISTs should be considered in the differential diagnosis of pediatric pts presenting with anaemia secondary to a GI hemorrhage.
  • GISTs in the pediatric population preferentially occur in the second decade of life, arise in the stomach, and do not exhibit an exon 11 c- KIT mutation.
  • Multicenter trials are needed to better elucidate the natural history, molecular phenotype, and therapies for these pts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013831.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Aggarwal S, Prakhar P, Kohli S, Negi A, Jauhari M, Bhalla S: Retrospective analysis and chemotherapy results in extra-nodal NHL patients in a large super-speciality hospital in North India. J Clin Oncol; 2009 May 20;27(15_suppl):e19566

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective analysis and chemotherapy results in extra-nodal NHL patients in a large super-speciality hospital in North India.
  • The type of NHL was B-Cell type (CD-20+ve) in 132(85%) and T-Cell type (CD 3+ve) in 22 (15%) cases.
  • Out of 77 extra-nodal cases, 31(20%) were GIT NHL (Stomach -16, Colon-8, Ileum-4, and Duodenum-3) and out of the rest 46 extra-nodal cases the site of origin was - head & neck-14, skin n soft tissues -8, primary CNS-6, testicular-4, para-spinal- 3, breast mass-3, perinephric-2, bones-2 and 1 each in cervix, lung mass, liver and cervical plexus.
  • 28 out of 31 were B-Cell type and 3 were T-Cell type.
  • In 2 patients the type of lymphoma could not be ascertained.
  • No surgery was performed in patients with stomach lymphoma.
  • RESULTS: Of all the extra-nodal cases chemotherapy was given to 39 patients - R-CHOP = 20 patients, CHOP = 13 patients, high dose MTX in primary CNS NHL = 6 patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961061.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Graefe T, Lubbing C, Bolling C, Muller-Hagen S, Leisner B, Fleet J, Ludtke FE, Blatter J, Suri A, Hanauske AR: Phase I study of pemetrexed plus paclitaxel in patients with solid tumor. J Clin Oncol; 2004 Jul 15;22(14_suppl):2103

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: 45 pts [31 M, 14 F; median age 59 (range 31-77); WHO performance status 0-1 (86.7%); prior chemotherapy (53.3%)] were enrolled.
  • Three drug-related discontinuations were anorexia, thrombocytopenia, and pancytopenia.
  • Stable disease occurred in pts with mesothelioma (3) and esophagus (2) cancers, and 1 pt each with thyroid, head and neck, lung, liver, pancreas, prostate, renal, and stomach cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28017047.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Jin M, Shen L, Hu B, Yu J, Wen Z, Su Y, Wang B, Chen L, Ying H, Chen L: Capecitabine (X) combined with cisplatin (P) as 1st-line therapy in Chinese patients (pts) with advanced gastric cancer (AGC). J Clin Oncol; 2004 Jul 15;22(14_suppl):4047

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Capecitabine (X) combined with cisplatin (P) as 1st-line therapy in Chinese patients (pts) with advanced gastric cancer (AGC).
  • 5-FU plus P is a standard treatment for AGC, producing response rates of 27-51% in randomized trials, although few Chinese data are available.
  • We evaluated the efficacy and safety of replacing the 5-FU component with X (Xeloda) as 1st-line therapy in Chinese AGC pts.
  • Prior radiotherapy or adjuvant chemotherapy was permitted.
  • RESULTS: Baseline characteristics of the 130 pts evaluable to date: 98 men, 32 women; median age 53.7 years (range 23-80); median Karnofsky PS 80 (60-100); 82% of pts had 1 metastatic site, and 18% had ≥2, the most common being the lymph nodes (44%), liver (42%), and stomach (17%).
  • The median treatment duration is currently 6 cycles (range 2-6).
  • Most events were easily managed with dose adjustment and/or suitable treatments, except 1 pt with anemia who withdrew after 2 cycles.
  • CONCLUSIONS: X combined with fractionated P is highly active and very well tolerated as first-line treatment for AGC, with comparable results to 5-FU/P.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014367.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Cadoo KA, Lowery MA, Cumiskey J, McCaffrey J, Carney DN: Long term follow-up of primary B and T cell non-Hodgkin's lymphoma (NHL) of the gastrointestinal (GI) tract. J Clin Oncol; 2009 May 20;27(15_suppl):e19516

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e19516 Background: Anthracycline based chemotherapy is the treatment of choice for aggressive primary lymphomas of the GI tract, with surgery reserved for management of complications.
  • We report long term follow up of 71 cases of primary GI NHL treated with chemotherapy and/or surgery.
  • Median age at diagnosis was 60 (15-83).
  • The 8 patients with MALT were treated with single agent chemotherapy; 7 (88%) are alive at median follow up of 8.5 years (2-16).
  • Of the aggressive lymphomas (63), all patients with T cell lymphoma had small bowel as primary site and histological evidence of celiac associated enteropathy, even in the absence of known celiac disease.
  • Primary sites of DLBCL were stomach 35 (67%), small bowel 11 (21%) & colon 6 (12%).
  • 39 (62%) patients underwent surgery at diagnosis due to acute presentation with perforation, bleeding or obstruction, or to obtain histology.
  • Following confirmed diagnosis, 61 patients received anthracycline based chemotherapy.
  • 2 patients with T cell lymphoma presented with perforation, were treated with surgery only and died of rapid disease progression.
  • 5 deaths in the DLBCL group were not related to cancer or treatment.
  • There was no difference in survival between patients treated with chemotherapy only and those who also underwent surgery.
  • CONCLUSIONS: Patients with aggressive primary B cell GI NHL have almost 70 % survival following anthracycline based chemotherapy.
  • However, in contrast, coeliac enteropathy associated T-cell lymphomas present with rapidly progressive disease & have a survival of < 20% with chemotherapy and/or surgery.
  • A novel therapeutic approach is required to improve outcome in this group.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960953.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Aziz SA, Banday MA, Mir MH: Comparative efficacy of adjuvant chemoradiation versus chemotherapy in surgically resected adenocarcinoma of stomach. J Clin Oncol; 2009 May 20;27(15_suppl):e15639

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative efficacy of adjuvant chemoradiation versus chemotherapy in surgically resected adenocarcinoma of stomach.
  • : e15639 Background: Outcome of carcinoma of stomach has not changed over the past decades and surgery remains the time tested primary modality of treatment.
  • The present study focuses to compare the efficacy of adjuvant chemoradiation Vs Chemotherapy alone in surgically resected adenocarcinoma of stomach.
  • ArmA received adjuvant chemoradiation and arm B received chemotherapy only.
  • CLV 20mg/m<sup>2</sup> I/V d1 - d5 followed by EBRT (45 GY) over 20 #s starting on d29.
  • Arm B received chemotherapy alone with Inj Cisplatin 100mg/m<sup>2</sup> divided over 3 days, Inj 5- FU 500 mg/m<sup>2</sup> I/V bolus d1 - d3 and Inj.
  • RESULTS: All patients were followed post treatment for EFS and PFS for a maximum period of 24 months with a median followup of 19 months.
  • Treatment related morbidity was significant in arm B.
  • CONCLUSIONS: Although interim survival trends favour adjuvant chemoradiation, yet results are not statistically significant necessitating a longer followup of these patients to arrive at a definite conclusion as for as decision regarding efficacy of chemoradiation is established.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962750.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Haid A, Knauer M, Köberle-Wührer R, Wenzl E: Sentinel node biopsy in breast cancer: technique and indication. Wien Klin Wochenschr; 2005 Feb;117(4):121-128

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : Sentinel node biopsy (SNB) has proved to be a useful and accurate procedure for lymph node staging in breast cancer and melanoma and should be standard of care in the treatment of these tumors.
  • In other malignancies (colon, rectum, stomach, esophagus, head and neck and thyroid, cervix uteri) it is still under investigation.
  • SNB in breast cancer was accepted as a sole and reliable diagnostic method in breast cancer by the panel of distinguished experts at the 8th international conference of primary therapy of early breast cancer 2003 in St. Gallen.
  • Albeit SNB could be shown to be safe after preoperative chemotherapy and in multicentric breast cancer, due to lack of sufficient data it is still under discussion in these cases.
  • Expedience of this procedure in other lymph node basins, along the mammaria interna vessels or in the infra- and supraclavicular region is considered to be at an investigative stage as well.
  • Detection of additional micrometastases that are found in 10-15% leads to an upgrading from N0 to N1.
  • Broad application and refurbishment led to scientific discussion of prognostic importance of micrometastases and its relevance regarding axillary dissection and adjuvant systemic treatment.
  • Findings of ongoing large prospective randomized trials like NSABP 32, Z0010 and Z0011 of the American College of Surgeons (ACOSOG), the AMAROS-Trial of the European Organisation of Research and Treatment of Cancer (EORTC) and the ALMANAC-Trial of the British Association of Surgical Oncology (BASO) will give a conclusive answer.
  • Significant improvement in morbidity and quality of life measurements could be revealed several times in unicentric and even in multicentric studies like ALMANAC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28108807.001).
  • [ISSN] 1613-7671
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  • [Keywords] NOTNLM ; Breast cancer / Indications / Sentinel node biopsy / Technique
  •  go-up   go-down


45. Stella G, Rojas Llimpe F, Barone C, Falcone A, Di Fabio F, Martoni A, Lamba S, Ceccarelli C, Siena S, Bardelli A, Pinto C: KRAS and BRAF mutational status as response biomarkers to cetuximab combination therapy in advanced gastric cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):e15503

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KRAS and BRAF mutational status as response biomarkers to cetuximab combination therapy in advanced gastric cancer patients.
  • : e15503 Background: The prognosis of advanced gastric cancer (GC) patients (pt) is still poor despite the introduction of new chemotherapy regimens.
  • In colorectal cancer (CRC) it has been demonstrated that KRAS or BRAF mutations are associated with resistance to treatment with the anti-EGFR mAbs.
  • We have assessed whether, and to what extent, the mutational profile of KRAS and BRAF genes affects the response to cetuximab combination therapy in GC.
  • METHODS: We have collected 44 tumor samples from pts affected by locally advanced or metastatic GC undergoing cetuximab combination therapy as first-line treatment in two consecutive phase II studies.
  • One case had the A11V variant that had been reported in hematopoietic and lymphoid tissue of the stomach.
  • In our cases, the mutational status of KRAS and BRAF genes does not correlate with the response to cetuximab-based therapy in advanced gastric cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962223.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Morales D, Beltran B, Hurtado de Mendoza F, Riva L, Quiñones P: Analysis of prognostic factors in patients with EBV positive diffuse large B cell lymphoma of the elderly. J Clin Oncol; 2009 May 20;27(15_suppl):e19542

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All cases were positive to the presence of EBV encoded RNA (EBER) by CISH and CD20 and/or Pax-5 expression by immunohistochemistry.Clinical data were reviewed retrospectively and patient's biopsies were analyzed for the immunohistochemical expression of BCL6, CD10, CD30 and MUM-1/IRF4 by tissue microarray (TMA) technique..
  • Extranodal disease occurred in 6/11 (54%) patients: pleura (n=2), suprarenal gland (n=1), stomach (n=1), cecum (n=1), bone (1), skin (1) and bone marrow (n=1).
  • Six patients had not received chemotherapy because they had bad status performance and 5 received CHOP-21 regimen.
  • CONCLUSIONS: EBV positive diffuse large B cell lymphoma of the elderly was related to high IPI, poor ECOG, frequent extranodal disease, poor response to treatment and very short survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960995.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Macdonald JS, Benedetti J, Smalley S, Haller D, Hundahl S, Jessup J, Ajani J, Gunderson L, Goldman B, Martenson J: Chemoradiation of resected gastric cancer: A 10-year follow-up of the phase III trial INT0116 (SWOG 9008). J Clin Oncol; 2009 May 20;27(15_suppl):4515

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 4515 Background: INT0116 (SWOG 9008) was a prospectively randomized phase III trial of postoperative adjuvant therapy utilizing 5-FU/leucovorin plus external beam radiation in 582 eligible cases of resected stage IB-IV(M0) stomach and gastroesophageal junction cancers.
  • In women the HR for therapy was 1.0(0.68-1.45).
  • The HR for therapy in diffuse histology cases was 0.97(0.62-1.40).
  • Second tumors represented a spectrum of types of neoplasms commonly occurring in this age group (median age 60 years).
  • Excessive numbers of tumors known to be caused by radiation and/or chemotherapy were not noted.
  • All subsets benefit from this treatment with the exception of cases with diffuse histology.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962700.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Jhawer M, Kindler HL, Wainberg Z, Ford J, Kunz P, Tang L, McCallum S, Kallender H, Shah MA, MET111643 Investigators and GlaxoSmithKline: Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): Interim results of a multicenter phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):4502

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): Interim results of a multicenter phase II study.
  • : 4502 Background: GSK089 is an oral, small-molecule inhibitor of cMET and VEGFR2/KDR, and has potent antitumor activity in cMET-amplified cell lines and xenografts. cMET is reportedly amplified, overexpressed and/or activated in GC, making it an attractive therapeutic target.
  • METHODS: Pts with distal esophagus, GE junction or stomach adenocarcinoma, 0-2 prior chemotherapy regimens, adequate organ function, measurable disease, and ECOG PS 0-2 are sequentially enrolled in 2 cohorts:.
  • Primary study endpoint (response) is assessed every 8 weeks. cMET amplification by FISH (≥2 copies of cMET per copy of chromosome 7) is not an entry criterion, but is determined on archival tissue for all pts.
  • Pre- and on-treatment tumor biopsies in select pts and plasma samples in all pts are analyzed for GSK089 effects on direct and downstream drug targets.
  • Only 1 possibly related grade 5 AE, death due to unknown cause, was noted.
  • Enrollment on the daily dosing schedule continues, now with mandatory pre- and on-treatment biopsies to better define cMET pathway and target inhibition with GSK089.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962690.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Kunisaki C, Akiyama H, Otsuka Y, Matsuda G, Nomura M, Hatori S, Imada T, Togo S, Ike H, Shimada H: Second-line chemotherapy with combined docetaxel and cisplatin for patients with far advanced gastric carcinoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):4214

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second-line chemotherapy with combined docetaxel and cisplatin for patients with far advanced gastric carcinoma.
  • To evaluate the efficacy and safety of a docetaxel and cisplatin combination for such population, therapeutic results were investigated.
  • All patients were administered prior chemotherapy with S-1 (80-100mg daily for 8 weeks or more: n=16), or low-dose fluorouracil and cisplatin combination therapy (fluorouracil; 500mg/m2, cisplatin; 5mg/m2, on day1-5, 8-12, 15-19, 22-26: n=10).
  • As second line, 60mg/m2 of docetacel and 60mg/m2 of cisplatin were administered every 3 weeks and treatment response was assessed after 3 courses.
  • RESULTS: The overall response rate of combined docetaxel and cisplatin therapy was 23.1% (6/26).
  • The site-specific response rates were 33.3, 43.0, 33.3, and 11.8% for patients with stomach, hematogenous, peritoneal, and lymph node metastasis, respectively.
  • At a median follow-up time of 11 months, 17 died of gastric cancer.
  • Overall median survival time (MST) was 6 months and time to progresson was 5 months after second line.
  • MST in patients with the third line (60mg/m2 of irinotecan, 60mg/m2 of cisplatin, every 3 weeks, 3 times) was 13 months whereas 5 months without the third line (p=0.0031).The adverse reactions in these populations were alopecia (96%), leucopenia (62%), neutropenia (62%), nausea and vomiting (38%), thrombocytopenia, anemia, and diarrhea.
  • All cases recovered with adequate medication.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013984.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Koucky K, Boxberger F, Albrecht H, Maennlein G, Wolff K, Ostermeier N, Schildberg C, Golcher H, Hohenberger W, Hahn EG, Wein A: Downsizing after palliative systemic chemotherapy with weekly high-dose 5-fluorouracil (5-FU) as a 24h-infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with metastatic adenocarcinomas of the stomach or the gastro-esophageal junction followed by secondary metastatic resection. J Clin Oncol; 2009 May 20;27(15_suppl):e15585

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Downsizing after palliative systemic chemotherapy with weekly high-dose 5-fluorouracil (5-FU) as a 24h-infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with metastatic adenocarcinomas of the stomach or the gastro-esophageal junction followed by secondary metastatic resection.
  • : e15585 Background: Due to the positive experience with combined AIO plus irinotecan (iri.) in a phase II trial (Möhler M et al, Br J Cancer 2005), this combination has been applied as first-line treatment in our department since 1999.
  • METHODS: 76 chemonaive patients (pts.) with histologically proven metastatic adenocarcinomas of the stomach or AEG tumours (tum.
  • Chemotherapy (chemoth.) schedule: iri. (80 mg/m<sup>2</sup> i.v. as 1h-infusion (inf.
  • This collective is presented here evidencing the efficacy of this interdisciplinary procedure in palliative (pall.) treatment of gastric cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962360.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Buyse ME, Pignon J, GASTRIC: Meta-analyses of randomized trials assessing the interest of postoperative adjuvant chemotherapy and prognostic factors in gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):4539

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meta-analyses of randomized trials assessing the interest of postoperative adjuvant chemotherapy and prognostic factors in gastric cancer.
  • : 4539 Background: Despite potentially curative resection of stomach cancer, 50%-90% of patients die of disease relapse.
  • Numerous randomized clinical trials (RCTs) compared surgery alone (S) to adjuvant chemotherapy (S+CT), but definitive evidence is lacking.
  • Our group has initiated an individual patient data (IPD)-based meta-analysis of all RCTs in the adjuvant gastric setting to quantify the potential benefit of S+CT over S, to study the role of various prognostic factors and their potential interactions with treatments.
  • Trials with radiotherapy, intraperitoneal chemotherapy, or immunotherapy were excluded.
  • Baselines variables included age, sex, tumour size (T) and stage, type of resection (D0, D1, D2 or more), performance status (PS) and geographic area.
  • The Logrank test was stratified by trial and treatment arm.
  • Interaction with treatment was explored with Cox model stratified on trial.
  • Treatment interactions were not identified for all but the stage.
  • Treatment effect appeared slightly stronger for patients with higher stages (HR for treatment effect from 0.88 in stage I to 0.66 in stage IV).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962986.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Petrakova K, Koukalová H, Soumarová R, Palácov' M, Blažkova S, Vyzula R: Relative risk (RR) of second malignancies (SM) in patients treated by "risk" radiotherapy (RT) or "risk" RT plus chemotherapy (CT) in comparison with patients treated by CT ± "non risk RT" for Hodgkin's disease (HD). J Clin Oncol; 2004 Jul 15;22(14_suppl):6695

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relative risk (RR) of second malignancies (SM) in patients treated by "risk" radiotherapy (RT) or "risk" RT plus chemotherapy (CT) in comparison with patients treated by CT ± "non risk RT" for Hodgkin's disease (HD).
  • Aim of our study was quantification of RR of SM in patients treated by "risk" RT ± CT (mantel field for breast cancer, and thyroid cancer, upper abdomen for stomach cancer, inverted Y or total nodal irradiation for colon cancer, inverted Y for gynecologic cancer) in comparison with patients treated by CT ± "non risk" RT.
  • METHODS: 851 patients (475 men and 376 women) with survival time after HD diagnosis >1 year were treated in MOÚ during 1967-1995.
  • 74 cases of SM developed in the cohort.
  • RESULTS: RR for the SM were as follows: breast cancer 5.39; lung cancer 0.77; colorectal cancer 10.3; stomach cancer 1.46; thyroid cancer 1.18; gynaecologic cancer 2.19.
  • CONCLUSION: The relative risk of solid tumors as second malignancies increased with the time of follow-up.
  • Treatment by "risk RT" increases RR of breast cancer, colorectal cancer, gynecologic cancer and slightly thyroid cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014399.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Kropacheva EI, Vorob'ev MV, Rudik AA, Kachalov SN, Khomenko AI: [Comparative evaluation of the motor-evacuation function of the stomach after functional operations for complicated duodenal ulcers]. Khirurgiia (Mosk); 2002;(6):22-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparative evaluation of the motor-evacuation function of the stomach after functional operations for complicated duodenal ulcers].
  • Motor-evacuatory disorders (MED) of the stomach in 114 patients who have undergone functional operations for duodenal ulcers were analyzed.
  • Some patients have severe disorders that require drug therapy.
  • US and endoscopy role in complex assessment and differential analysis of stomach evacuatory disorders is emphasized.
  • [MeSH-major] Duodenal Ulcer / surgery. Gastric Emptying. Stomach / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12109180.001).
  • [ISSN] 0023-1207
  • [Journal-full-title] Khirurgiia
  • [ISO-abbreviation] Khirurgiia (Mosk)
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia
  •  go-up   go-down


54. Zyrianov BN, Vusik MV, Kritskaia NG: [Clinico-morphological assessment of early and late results of laser therapy of the anastomosis area after radical surgeries for stomach cancer]. Arkh Patol; 2003 Nov-Dec;65(6):17-21
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinico-morphological assessment of early and late results of laser therapy of the anastomosis area after radical surgeries for stomach cancer].
  • The study included 52 patients after gastrectomy for carcinoma of the proximal part of the stomach.
  • Endoscopic laser therapy was made in 32 patients to reduce inflammation in the anastomosis zone 2-3 weeks after surgery.
  • Drug therapy was made in 20 patients within the same time period.
  • It is revealed that application of copper vapor laser early after surgery reduces edema and inflammation in the anastomosis zone for 2 weeks as well as accelerates the growth of granulation tissue forming a delicate scar thus preventing formation of scar stenosis.
  • [MeSH-major] Gastroenteritis / pathology. Gastroenterostomy / adverse effects. Low-Level Light Therapy. Postoperative Care. Stomach Neoplasms / surgery
  • [MeSH-minor] Biopsy. Constriction, Pathologic / drug therapy. Constriction, Pathologic / etiology. Constriction, Pathologic / pathology. Constriction, Pathologic / radiotherapy. Gastrectomy. Gastric Mucosa / drug effects. Gastric Mucosa / pathology. Gastric Mucosa / radiation effects. Gastrointestinal Agents / therapeutic use. Humans. Intestinal Mucosa / drug effects. Intestinal Mucosa / pathology. Intestinal Mucosa / radiation effects. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Gastroenteritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14964962.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia
  • [Chemical-registry-number] 0 / Gastrointestinal Agents
  •  go-up   go-down


55. Sen M, Turan M, Karadayi K, Ugurlu L, Elagoz S: Isolated hepatic tuberculous pseudometastasis co-existent with adenocarcinoma of the stomach; report of a case. Acta Chir Belg; 2004 Oct;104(5):601-3
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated hepatic tuberculous pseudometastasis co-existent with adenocarcinoma of the stomach; report of a case.
  • A 10 x 9 mm metastasis-like lesion in segment V of the liver was detected, when a 70-year-old man was operated on for adenocarcinoma of the stomach.
  • Since exact diagnosis of the hepatic lesion could not be made by frozen sections, the lesion was excised, considering it to be a metastasis of gastric adenocarcinoma.
  • Bacteriologic and pathologic studies established a diagnosis of isolated tuberculosis of the liver.
  • A good response to antituberculous drug therapy was noted.
  • [MeSH-major] Adenocarcinoma / pathology. Liver Neoplasms / pathology. Liver Neoplasms / secondary. Stomach Neoplasms / pathology. Tuberculosis, Hepatic / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15571035.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


56. Sevcencu C: Electrical stimulation - an evolving concept in the treatment of colonic motor dysfunctions. Neurogastroenterol Motil; 2006 Nov;18(11):960-70
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Electrical stimulation - an evolving concept in the treatment of colonic motor dysfunctions.
  • Electrical stimulation of digestive organs is a new approach for the treatment of dismotility-based diseases affecting the gastrointestinal (GI) tract.
  • The most significant advancement in this field has been obtained with stomach stimulation.
  • Similarly, electrical stimulation of the colon may become a valuable alternative to drug therapy and surgical procedures in the treatment of colonic motor dysfunctions.
  • [MeSH-major] Colonic Diseases / therapy. Electric Stimulation Therapy

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17040406.001).
  • [ISSN] 1350-1925
  • [Journal-full-title] Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society
  • [ISO-abbreviation] Neurogastroenterol. Motil.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 52
  •  go-up   go-down


57. Corá LA, Américo MF, Oliveira RB, Baffa O, Moraes R, Romeiro FG, Miranda JR: Disintegration of magnetic tablets in human stomach evaluated by alternate current biosusceptometry. Eur J Pharm Biopharm; 2003 Nov;56(3):413-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disintegration of magnetic tablets in human stomach evaluated by alternate current biosusceptometry.
  • Oral administration is the most convenient route for drug therapy.
  • The knowledge of the gastrointestinal transit and specific site for drug delivery is a prerequisite for development of dosage forms.
  • Results showed that ACB is efficient to characterize the disintegration of dosage forms in the stomach, being a research tool for the development of new pharmaceutical dosage forms.
  • [MeSH-major] Drug Delivery Systems / instrumentation. Magnetics / instrumentation. Stomach / metabolism. Tablets / pharmacokinetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14602185.001).
  • [ISSN] 0939-6411
  • [Journal-full-title] European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V
  • [ISO-abbreviation] Eur J Pharm Biopharm
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Dosage Forms; 0 / Tablets
  •  go-up   go-down


58. Corá LA, Andreis U, Romeiro FG, Américo MF, Oliveira RB, Baffa O, Miranda JR: Magnetic images of the disintegration process of tablets in the human stomach by ac biosusceptometry. Phys Med Biol; 2005 Dec 7;50(23):5523-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic images of the disintegration process of tablets in the human stomach by ac biosusceptometry.
  • Oral administration of solid dosage forms is usually preferred in drug therapy.
  • The non-invasive technique of ac biosusceptometry has been introduced as an alternative in studies focusing on gastrointestinal motility and, more recently, to evaluate the behaviour of magnetic tablets in vivo.
  • The aim of this work was to employ a multisensor ac biosusceptometer system to obtain magnetic images of disintegration of tablets in vitro and in the human stomach.
  • The results showed that the transition between the magnetic marker and the magnetic tracer characterized the onset of disintegration (t(50)) and occurred in a short time interval (1.1 +/- 0.4 min).
  • [MeSH-major] Stomach / drug effects. Stomach / pathology
  • [MeSH-minor] Administration, Oral. Adult. Biological Availability. Chemistry, Pharmaceutical / methods. Digestive System. Dosage Forms. Drug Delivery Systems. Female. Humans. Image Processing, Computer-Assisted. Magnetics. Male. Solubility. Tablets. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16306649.001).
  • [ISSN] 0031-9155
  • [Journal-full-title] Physics in medicine and biology
  • [ISO-abbreviation] Phys Med Biol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dosage Forms; 0 / Tablets
  •  go-up   go-down


59. Skoropad VIu, Berdov BA: [Surgical treatment of advanced cancer of the stomach]. Khirurgiia (Mosk); 2004;(11):30-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of advanced cancer of the stomach].
  • Experience in surgical treatment of gastric cancer with distant metastases was analyzed.
  • Surgery was performed as gastrectomy (27 patients), subtotal resection of the stomach (25) and extirpation of the gastric stump (4); metastatic tumors were removed in half of the patients.
  • But today, extended surgeries can be performed in uncomplicated forms of gastric cancer to improve quality of patients' life and to carry out drug therapy more successfully.
  • [MeSH-major] Stomach Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Postoperative Period. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15602459.001).
  • [ISSN] 0023-1207
  • [Journal-full-title] Khirurgiia
  • [ISO-abbreviation] Khirurgiia (Mosk)
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia
  •  go-up   go-down


60. Ma BB, Hui EP, Mok TS: Population-based differences in treatment outcome following anticancer drug therapies. Lancet Oncol; 2010 Jan;11(1):75-84
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Population-based differences in treatment outcome following anticancer drug therapies.
  • Population-based differences in toxicity and clinical outcome following treatment with anticancer drugs have an important effect on oncology practice and drug development.
  • These differences arise from complex interactions between biological and environmental factors, which include genetic diversity affecting drug metabolism and the expression of drug targets, variations in tumour biology and host physiology, socioeconomic disparities, and regional preferences in treatment standards.
  • This review is a critical overview of population-based differences in the four most prevalent cancers in the world: lung, breast, colorectal, and stomach cancer.
  • Particular attention is given to the clinical relevance of such knowledge in terms of the individualisation of drug therapy and in the design of clinical trials.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Neoplasms / drug therapy. Neoplasms / epidemiology. Pharmacogenetics. Precision Medicine
  • [MeSH-minor] Breast Neoplasms / drug therapy. Breast Neoplasms / epidemiology. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / epidemiology. Continental Population Groups. Environment. Female. Genetic Predisposition to Disease. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / epidemiology. Male. Patient Selection. Risk Assessment. Risk Factors. Stomach Neoplasms / drug therapy. Stomach Neoplasms / epidemiology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20129130.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 91
  •  go-up   go-down


61. Klausner EA, Lavy E, Friedman M, Hoffman A: Expandable gastroretentive dosage forms. J Control Release; 2003 Jun 24;90(2):143-62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They were originally created for possible veterinary use, but later the design was modified for enhanced drug therapy in humans.
  • These GRDFs are easily swallowed and reach a significantly larger size in the stomach due to swelling or unfolding processes that prolong their gastric retention time (GRT).
  • After drug release, their dimensions are minimized with subsequent evacuation from the stomach.
  • Gastroretentivity is enhanced by the combination of substantial dimensions with high rigidity of the dosage form to withstand the peristalsis and mechanical contractility of the stomach.
  • Narrow absorption window drugs compounded in such systems have improved in vivo absorption properties.
  • [MeSH-major] Delayed-Action Preparations / administration & dosage. Digestive System / drug effects. Drug Delivery Systems / methods
  • [MeSH-minor] Animals. Dosage Forms. Gastrointestinal Motility / drug effects. Gastrointestinal Motility / physiology. Humans. Intestinal Absorption / drug effects. Intestinal Absorption / physiology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12810298.001).
  • [ISSN] 0168-3659
  • [Journal-full-title] Journal of controlled release : official journal of the Controlled Release Society
  • [ISO-abbreviation] J Control Release
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Delayed-Action Preparations; 0 / Dosage Forms
  • [Number-of-references] 143
  •  go-up   go-down


62. Reyes JD: Intestinal transplantation. Semin Pediatr Surg; 2006 Aug;15(3):228-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The modern era of clinical solid organ transplantation has just passed the half-century mark, having closed the 20th century with the long sought clinical success in intestinal transplantation and combinations of abdominal organs (liver-intestine, intestine-pancreas, liver-stomach-pancreas-intestine).
  • Developments in technique, organ preservation, peri-operative care, and immunosuppressive management over the last 15 years have made intestinal transplantation an effective treatment for children with intestinal failure.
  • The ripple effects of these advances have resulted in the March 2001 Medicare report which provided a national coverage decision of the Social Security Act for intestinal Transplantation.
  • In this article, we describe the basis for successful clinical intestinal transplantation, reviewing progress with surgical technique, posttransplant management, and the evolution of immunosuppressive drug therapy.
  • [MeSH-minor] Child. Graft Survival. Humans. Immunosuppressive Agents / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16818144.001).
  • [ISSN] 1055-8586
  • [Journal-full-title] Seminars in pediatric surgery
  • [ISO-abbreviation] Semin. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  • [Number-of-references] 22
  •  go-up   go-down


63. SHsirinov ZT, Salikhov IaS, Kurbanov FS: [Diagnosis and surgical treatment of gastric ulcers of proximal localization]. Khirurgiia (Mosk); 2004;(10):20-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and surgical treatment of gastric ulcers of proximal localization].
  • Over 15 years 208 patients with ulcers of the proximal part of the stomach (36 cardial and 172 subcardial) underwent surgery that constitutes 17,5% of all gastric ulcers.
  • Successful surgical treatment of a proximal part of the stomach is based on timely complex diagnosis.
  • High rate of complications dictates that conservative treatment of these ulcers should be limited to 6 months - 1 year.
  • Indications for surgery must be also regarded when up-to-date drug therapy is ineffective during 2-3 months.
  • Proximal and distal resection of the stomach are the main methods in surgical treatment of patients with benign ulcers of the cardia and subcardia.
  • [MeSH-major] Gastrectomy / methods. Stomach Ulcer / diagnosis. Stomach Ulcer / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15477820.001).
  • [ISSN] 0023-1207
  • [Journal-full-title] Khirurgiia
  • [ISO-abbreviation] Khirurgiia (Mosk)
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia
  •  go-up   go-down


64. Suleyman H, Cadirci E, Albayrak A, Polat B, Halici Z, Koc F, Hacimuftuoglu A, Bayir Y: Comparative study on the gastroprotective potential of some antidepressants in indomethacin-induced ulcer in rats. Chem Biol Interact; 2009 Jul 15;180(2):318-24
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinical studies have shown that anxiolytic and antidepressant drug therapy benefits patients with ulcers.
  • Many antidepressant drugs have been shown experimentally to produce antiulcer activity in various ulcer models.
  • This study investigated the antiulcer activities of tianeptine, trazodone, and venlafaxine on indomethacin-induced ulcers in rats; and evaluated tianeptine's effects on oxidant and antioxidant parameters in rat stomach tissue.
  • Tianeptine significantly prevented the decrease in glutathione (GSH) content that occurred in the indomethacin-only group's damaged stomach tissues.
  • All doses of tianeptine, but especially the 25 mg/kg dose, significantly decreased catalase (CAT) activity in stomach tissue, compared to the control.
  • All doses of tianeptine eliminated the decrease in superoxide dismutase (SOD) activity in the stomach tissue of rats given indomethacin.
  • [MeSH-major] Anti-Ulcer Agents / therapeutic use. Antidepressive Agents / pharmacology. Indomethacin / toxicity. Stomach Ulcer / chemically induced. Stomach Ulcer / drug therapy
  • [MeSH-minor] Animals. Cyclohexanols / pharmacology. Famotidine / therapeutic use. Male. Rats. Rats, Inbred WF. Thiazepines / pharmacology. Trazodone / pharmacology. Venlafaxine Hydrochloride

  • MedlinePlus Health Information. consumer health - Antidepressants.
  • Hazardous Substances Data Bank. TRAZODONE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. INDOMETHACIN .
  • Hazardous Substances Data Bank. FAMOTIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19497431.001).
  • [ISSN] 1872-7786
  • [Journal-full-title] Chemico-biological interactions
  • [ISO-abbreviation] Chem. Biol. Interact.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Anti-Ulcer Agents; 0 / Antidepressive Agents; 0 / Cyclohexanols; 0 / Thiazepines; 0T493YFU8O / tianeptine; 5QZO15J2Z8 / Famotidine; 7D7RX5A8MO / Venlafaxine Hydrochloride; XXE1CET956 / Indomethacin; YBK48BXK30 / Trazodone
  •  go-up   go-down


65. Duong PH, Zulian GB: Disappearance of a stutter shortly before death. Am J Hosp Palliat Care; 2007 Apr-May;24(2):141-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The stutter appeared to have been overcome using a combination therapy of sophrology, self-regulation, and drug therapy.
  • She repeatedly refused to have a nasogastric tube inserted to extract fecal matter from the stomach.
  • This patient consequently repossessed her own language of expression in a body that was shattered by cancerous illness and the consequences of treatments.
  • [MeSH-major] Complementary Therapies. Ovarian Neoplasms / complications. Palliative Care. Stuttering / therapy


66. Magnuson BL, Clifford TM, Hoskins LA, Bernard AC: Enteral nutrition and drug administration, interactions, and complications. Nutr Clin Pract; 2005 Dec;20(6):618-24
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enteral nutrition and drug administration, interactions, and complications.
  • The same access device is increasingly being used to deliver medications, which provides cost savings but also creates new challenges.
  • Cost savings can be negated if the concomitant administration of nutrition elicits a decrease in bioavailability due to incompatibilities that alter drug or nutrition therapy.
  • Feeding tubes can deliver nutrients and drugs to the stomach, small bowel, or both, with optimal efficacy of medications depending on delivery to the appropriate segment of the gastrointestinal tract.
  • Obstruction of the enteral access device may occur when specialized medication formulations are altered inappropriately.
  • Occasionally, the enteral formula should be changed to modify the content of free water, fiber, electrolytes, or vitamins that may interfere with the drug therapy.
  • Intolerance to enteral nutrition such as abdominal distention and diarrhea may be the result of the medication, and the causative agent should be identified to improve patient comfort.
  • This article will address optimal drug delivery via enteral access devices and possible complications associated with therapy.
  • [MeSH-major] Enteral Nutrition / methods. Food-Drug Interactions / physiology. Pharmaceutical Preparations / administration & dosage
  • [MeSH-minor] Biological Availability. Drug Administration Routes. Humans

  • MedlinePlus Health Information. consumer health - Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16306299.001).
  • [ISSN] 0884-5336
  • [Journal-full-title] Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition
  • [ISO-abbreviation] Nutr Clin Pract
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pharmaceutical Preparations
  • [Number-of-references] 37
  •  go-up   go-down


67. Korica M, Petaković G, Gavrilović S: [Surgical treatment of perforated gastric ulcer]. Med Pregl; 2002 Nov-Dec;55(11-12):513-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of perforated gastric ulcer].
  • INTRODUCTION: Peptic ulcer perforation is a complication of ulcer disease which requires urgent surgical treatment.
  • The aim of this paper was to point out our experience in surgical treatment of perforated peptic ulcer.
  • MATERIAL AND METHODS: This retrospective study analyzes results of surgical treatment in 365 patients with perforated peptic ulcer during the period January 1996 to December 2000.
  • The most frequent surgical procedures in treatment of peptic ulcer perforation were: simple closure with biopsy (55.88%), excision of the ulcer with a pyloroplasty and vagotomy (35.29%) as nonresection surgical procedures and stomach resection after Billroth II (8.83%).
  • CONCLUSIONS: The methods of choice in surgical treatment of gastric ulcer perforation are nonresection surgical procedures with drug therapy and eradication of Helicobacter pylori, if present.
  • [MeSH-major] Peptic Ulcer Perforation / surgery. Stomach Ulcer / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12712896.001).
  • [ISSN] 0025-8105
  • [Journal-full-title] Medicinski pregled
  • [ISO-abbreviation] Med. Pregl.
  • [Language] hrv
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Yugoslavia
  •  go-up   go-down


68. Quintero M, Mackenzie N, Brennan PA: Hypoxia-inducible factor 1 (HIF-1) in cancer. Eur J Surg Oncol; 2004 Jun;30(5):465-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It contributes to local and systemic tumour progression as well as potentially compromising radiotherapy and chemotherapy.
  • Over-expression of HIF-1 has been associated with increased patient mortality in several cancer types including breast, stomach, cervical, endometrial and ovarian cancers.
  • The pharmacological manipulation of HIF-1 has marked effects on tumour growth, and it could prove to be an important target for drug therapy, both in cancer and in other hypoxia-dependent disease states.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15135470.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Nuclear Proteins; 0 / Transcription Factors
  • [Number-of-references] 34
  •  go-up   go-down


69. Gomes ML, de Souza Braga AC, de Mattos DM, de Souza Freitas R, de Paula EF, Bezerra RJ, Bernardo-Filho M: Effect of mitomycin-C on the bioavailability of the radiopharmaceutical (99m)technetium-phytic acid in mice: a model to evaluate the toxicological effect of a chemical drug. J Appl Toxicol; 2002 Jan-Feb;22(1):85-7
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of mitomycin-C on the bioavailability of the radiopharmaceutical (99m)technetium-phytic acid in mice: a model to evaluate the toxicological effect of a chemical drug.
  • It is generally accepted that a variety of factors can alter the biodistribution of radiopharmaceuticals and one such factor is drug therapy.
  • Because patients on chemotherapeutic treatment receive a radiopharmaceutical in a nuclear medicine procedure, we have studied in Balb/c mice the effect of mitomycin-C on the biodistribution of the radiopharmaceutical (99m)Tc-phytic acid ((99m)Tc-PHY) used in hepatic scintigraphy.
  • Mitomycin-C is an antineoplastic agent obtained from Streptomyces caesptosus and is used on the treatment of disseminated adenocarcinoma of the stomach or pancreas.
  • The results have shown that the percentage radioactivity has been increased in stomach, spleen, lung, thyroid and bone, decreased in pancreas and thymus and not altered in ovary, uterus, kidney, heart, liver and brain.
  • The changes in the distribution of (99m)Tc-PHY may be the result of metabolic processes and/or therapeutic actions produced by the administration of mitomycin-C.
  • [MeSH-minor] Animals. Biological Availability. Female. Mice. Mice, Inbred BALB C. Models, Animal. Tissue Distribution

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 John Wiley & Sons, Ltd.
  • (PMID = 11807933.001).
  • [ISSN] 0260-437X
  • [Journal-full-title] Journal of applied toxicology : JAT
  • [ISO-abbreviation] J Appl Toxicol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 50SG953SK6 / Mitomycin; 7IGF0S7R8I / Phytic Acid
  •  go-up   go-down


70. Lefebvre RA: Pharmacological characterization of the nitrergic innervation of the stomach. Verh K Acad Geneeskd Belg; 2002;64(3):151-66
Hazardous Substances Data Bank. NITRIC OXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacological characterization of the nitrergic innervation of the stomach.
  • The efferent neurons involved at the level of the stomach are nonadrenergic noncholinergic.
  • Nitric oxide (NO) is mediating, together with vasoactive intestinal polypeptide (VIP) as parallel cotransmitter, the nonadrenergic noncholinergic neurotransmission of the proximal stomach.
  • Stimulating or inhibiting the gastric nitrergic neurons might be a target for drug therapy in functional dyspepsia or gastro-esophageal reflux, respectively.
  • [MeSH-major] Dyspepsia / etiology. Neural Pathways / pathology. Nitric Oxide / metabolism. Stomach / innervation

  • MedlinePlus Health Information. consumer health - Indigestion.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12238240.001).
  • [ISSN] 0302-6469
  • [Journal-full-title] Verhandelingen - Koninklijke Academie voor Geneeskunde van België
  • [ISO-abbreviation] Verh. K. Acad. Geneeskd. Belg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Free Radical Scavengers; 0 / Neurotransmitter Agents; 31C4KY9ESH / Nitric Oxide; 37221-79-7 / Vasoactive Intestinal Peptide; EC 1.15.1.1 / Superoxide Dismutase
  • [Number-of-references] 57
  •  go-up   go-down


71. Baffa O, Cora L, Americo M, Fonseca P, Oliveira R, A Miranda J: Magnetic images of pharmaceutical dosage forms in the human gastrointestinal tract. Conf Proc IEEE Eng Med Biol Soc; 2005;7:7254-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oral administration with solid dosage forms is a common route in the drug therapy widely used.
  • The drug release by the disintegration process occurs in several gastrointestinal tract (GIT) regions.
  • AC Biosusceptometry (ACB) was originally proposal to characterize the disintegration process of tablets in vitro and in the human stomach, through changes in magnetic signals.
  • The ACB showed accuracy to quantify the gastric residence time, the intestinal transit time and the magnetic images allowed to visualize the disintegration of magnetic formulations in the GIT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17281954.001).
  • [ISSN] 1557-170X
  • [Journal-full-title] Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference
  • [ISO-abbreviation] Conf Proc IEEE Eng Med Biol Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Matsumura M, Matsui T, Hatakeyama S, Matake H, Uno H, Sakurai T, Yao T, Oishi T, Iwashita A, Fujioka T: Prevalence of Helicobacter pylori infection and correlation between severity of upper gastrointestinal lesions and H. pylori infection in Japanese patients with Crohn's disease. J Gastroenterol; 2001 Nov;36(11):740-7
MedlinePlus Health Information. consumer health - Peptic Ulcer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The relationship between drug therapy and the prevalence of H. pylori infection was also analyzed.
  • The lesions observed included ulcers, erosion, and "bamboo joint-like lesions" of the stomach, and ulcers, erosion, stenosis, and elevated lesions of the duodenum.
  • The analysis of a possible relationship between a history of drug therapy and the low prevalence of H. pylori infection in CD patients showed that the prevalence of H. pylori infection was significantly lower in patients who had received antibiotics for 2 weeks or more (P = 0.002).
  • [MeSH-minor] Adolescent. Adult. Aged. Anti-Bacterial Agents / therapeutic use. Child. Cross-Sectional Studies. Endoscopy, Gastrointestinal. Female. Humans. Japan. Male. Middle Aged. Severity of Illness Index. Time Factors


73. Hoffmann U, Hecker U, Abel P: Acute poisoning by pirimicarb: clinical and toxicological features. Clin Toxicol (Phila); 2008 Aug;46(7):694-96
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENT: A 68-year-old male ingested an unknown amount of pirimicarb and developed cholinergic symptoms immediately, accompanied by seizures.
  • INTERVENTIONS: He was admitted in the Intensive Care Unit (ICU) and received intensive care including intubation for hypoxemia following seizures and drug therapy of hypertensive dysregulation.
  • MEASUREMENTS AND RESULTS: Pirimicarb stomach, blood, and urine levels were determined on admission and during hospitalisation.
  • The butyryl cholinesterase (BChE) activity was at the lower level of detection on the admission and recovered during the following 24 hours.
  • [MeSH-minor] Aged. Butyrylcholinesterase / blood. Cholinesterase Inhibitors / blood. Cholinesterase Inhibitors / poisoning. Humans. Male. Poisoning / blood. Poisoning / enzymology. Poisoning / therapy. Suicide

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PIRIMICARB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18608305.001).
  • [ISSN] 1556-9519
  • [Journal-full-title] Clinical toxicology (Philadelphia, Pa.)
  • [ISO-abbreviation] Clin Toxicol (Phila)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbamates; 0 / Cholinesterase Inhibitors; 0 / Insecticides; 0 / Pyrimidines; 1I93PS935T / pirimicarb; EC 3.1.1.- / Butyrylcholinesterase
  •  go-up   go-down


74. Stepanov EA, Razumovskiĭ AIu, Bataev S-, Alkhasov AB, Nurik VI, Mart'ianov AV, Bogaeva II: [Treatment policy for children with gastroesophageal reflux complicated by Barrett esophagus]. Khirurgiia (Mosk); 2002;(11):8-13
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment policy for children with gastroesophageal reflux complicated by Barrett esophagus].
  • Twenty-four-hour pH-metry and manometry of the esophagus, scintigraphy and contrast roentgenoscopy of the esophagus were used for diagnosis of GER.
  • All the children underwent biopsy of mucosa membrane of distal esophagus.
  • Metaplasia of esophageal epithelium by intestinal type (IT) in combination with one by gastric type (GT) were revealed in 8 children, metaplasia by gastric type alone (epithelium of gastric and fundal parts of the stomach)--in 8 children.
  • It esophageal stenosis is not long or is absent, fundoplication by Nissen (4 children) and drug therapy (6 children) are performed.
  • Other methods of treatment do not exclude probability of esophageal adenocarcinoma.
  • [MeSH-major] Barrett Esophagus / etiology. Gastroesophageal Reflux / complications. Gastroesophageal Reflux / therapy
  • [MeSH-minor] Adolescent. Biopsy. Child. Child, Preschool. Combined Modality Therapy / standards. Diet, Reducing. Drug Therapy, Combination. Esophagoplasty / methods. Esophagus / drug effects. Esophagus / pathology. Esophagus / physiopathology. Esophagus / surgery. Female. Humans. Infant. Male. Metaplasia. Supine Position / physiology


75. Bergert FW, Conrad D, Ehrenthal K, Fessler J, Gross J, Gundermann K, Kluthe B, Lang Heinrich W, Liesenfeld A, Loew PG, Luther E, Pchalek R, Seffrin J, Sterzing A, Wolfring HJ, Zimmermann U, Guidelines Group Hesse: Pharmacotherapy Guidelines by Family Doctors for Family Doctors: Pharmacotherapy guidelines for the aged by family doctors for the use of family doctors: Part D Basic conditions supporting drug treatment. Int J Clin Pharmacol Ther; 2009 May;47(5):289-302
MedlinePlus Health Information. consumer health - Exercise for Seniors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacotherapy guidelines for the aged by family doctors for the use of family doctors: Part D Basic conditions supporting drug treatment.
  • Physiological changes in old age: loss of muscle mass; reduction in bone mass; percentage of fat increased; lower amount of body water; lack of thirst; diminishing kidney function (caution: sufficient intake of fluids: 1.5-2 l and moderate intake of protein 8 g/kg body weight); reduced secretion of digestive enzymes, delayed emptying of stomach (which means premature feeling of repletion).
  • Moreover, moderate physical exercise is often more effective in treating chronic disease than drug therapy e.g. heart failure, coronary heart disease, asthma/COPD, stroke, diabetes mellitus Type 2, degenerative diseases of the joints, depression and others.
  • [MeSH-minor] Aged. Family Practice. Humans. Nutrition Assessment. Nutrition Disorders / physiopathology. Nutrition Disorders / therapy. Nutritional Status. Physical Endurance. Resistance Training

  • MedlinePlus Health Information. consumer health - Exercise and Physical Fitness.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19473591.001).
  • [ISSN] 0946-1965
  • [Journal-full-title] International journal of clinical pharmacology and therapeutics
  • [ISO-abbreviation] Int J Clin Pharmacol Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


76. Amorim LF, Catanho MT, Terra DA, Brandão KC, Holanda CM, Jales-Júnior LH, Brito LM, Gomes ML, De Melo VG, Bernardo-Filho M, Cavalcanti Jales RL: Assessment of the effect of Punica granatum (pomegranata) on the bioavailability of the radiopharmaceutical sodium pertechnetate (99mTc) in Wistar rats. Cell Mol Biol (Noisy-le-grand); 2003 Jun;49(4):501-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is generally accepted that a variety of factors other than disease can alter the bioavailability of radiopharmaceuticals and one such factor is the drug therapy.
  • Punica granatum (pomegranata) is used as food or as medication in folk medicine for antiviral, anthelmintic, antifungal, antibacterial and antimicrobial activity.
  • The organs were isolated (brain, heart, thyroid, liver, lungs, kidneys, stomach, testis, intestines, pancreas, spleen, bladder, muscle and bone), the radioactivity determined in a well counter, the percentages of radioactivity (%ATI) in the organs were calculated and statistical analyses were performed by Wilcoxon test (p < 0.05).
  • The results have shown a significant (p < 0.05) increase of the activity of the Na(99m)TcO4 in spleen, heart, stomach, liver, stout bowel, pancreas, lungs and testis at 5 min.
  • Twenty minutes after the administration of the radiopharmaceutical, the analysis of the results reveals a significant (p < 0.05) increase of the %ATI in heart, stomach, femur, pancreas, lungs and kidneys.
  • Forty minutes after the administration of the Na(99m)TcO4, the results show a significant (p < 0.05) increase in spleen, brain, heart, stomach, liver, stout bowel, muscle, femur, lungs, pancreas, kidneys and testis.
  • These results can be justified by therapeutic effect of this extract and/or by generation of active metabolites capable to interfere with the biodistribution of the studied radiopharmaceutical.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12899440.001).
  • [ISSN] 0145-5680
  • [Journal-full-title] Cellular and molecular biology (Noisy-le-Grand, France)
  • [ISO-abbreviation] Cell. Mol. Biol. (Noisy-le-grand)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Plant Extracts; A0730CX801 / Sodium Pertechnetate Tc 99m
  •  go-up   go-down


77. Patrushev NB, Koviazina IO, Lazebnik LB: [Conservative treatment of patients with varicose esophagus veins cirrhosis]. Eksp Klin Gastroenterol; 2010;(11):40-5
MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Conservative treatment of patients with varicose esophagus veins cirrhosis].
  • Varicose veins of the esophagus and stomach diagnosed in 50-80% of patients with liver cirrhosis and complicated by hemorrhage in 30-50%.
  • Conservative treatments don't always yield the desired result, which motivates the search for new pharmacological treatments of portal hypertension complications.
  • The study didn't include patients with the presence of VEV III degree; hepatocellular insufficiency C class on the Child-Pugh classification; extrahepatic form of portal hypertension and patients with circulatory failure requiring continuous drug therapy.
  • All patients received therapy with flavonoids (diosmin with hesperidin) for 12 weeks.
  • Efficacy of treatment was evaluated by endoscopic picture of the esophageal mucosa and the state of VEV at 4 and 12 weeks.
  • RESULTS: Treatment with the flavonoids hesperidin with diasminom showed a positive result in the form of reducing the VEV and reduced the number of varicose veins with a statistically significant in patients with alcoholic liver cirrhosis (p < 0.05).
  • CONCLUSION: The results indicated the effectiveness of therapy with flavonoids hesperidin with diasmin at portal hypertension in patients with alcoholic cirrhosis, which allows to include them in the complex treatment of medicamental prophylaxis of variceal bleeding.
  • [MeSH-major] Diosmin / administration & dosage. Esophageal and Gastric Varices / prevention & control. Gastrointestinal Hemorrhage / drug therapy. Hesperidin / administration & dosage. Liver Cirrhosis / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Severity of Illness Index. Time Factors

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21485513.001).
  • [ISSN] 1682-8658
  • [Journal-full-title] Ėksperimental'nai︠a︡ i klinicheskai︠a︡ gastroėnterologii︠a︡ = Experimental & clinical gastroenterology
  • [ISO-abbreviation] Eksp Klin Gastroenterol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 7QM776WJ5N / Diosmin; E750O06Y6O / Hesperidin
  •  go-up   go-down


78. Golder W: [Propolis. The bee glue as presented by the Graeco-Roman literature]. Wurzbg Medizinhist Mitt; 2004;23:133-45

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Only rarely, a single drug therapy was using propolis was carried out.
  • Finally, bee glue proved successful for the treatment of chronic backache and pain in the hip as well as fresh injuries of muscles and tendons.
  • However, the successful use of propolis in diseases of the stomach and liver has ben reported solely by Alexander of Tralles (6th century AD).
  • Interestingly, radiation therapists have adopted the ancient remedy and use propolis successfully for the treatment of actinic stomatitis and mucositis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15630803.001).
  • [ISSN] 0177-5227
  • [Journal-full-title] Wurzburger medizinhistorische Mitteilungen
  • [ISO-abbreviation] Wurzbg Medizinhist Mitt
  • [Language] GER
  • [Publication-type] English Abstract; Historical Article; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 9009-62-5 / Propolis
  •  go-up   go-down


79. Valdespino-Gómez VM, López-Garza JR, González-Alemán JC, Valdespino-Castillo VE: [Emergencies and urgent medical-surgical conditions attended at a comprehensive cancer center]. Cir Cir; 2006 Sep-Oct;74(5):359-68

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Atencián de las emergencias y urgencias médico-quirúrgicas en un hospital oncológico.
  • The most frequent baseline diseases were breast, colorectal, cervical, lung and stomach carcinomas.
  • Data evaluating the use of analgesic drug therapy for cancer pain alone indicate that 80% of patients report adequate analgesia.
  • The Urgent Care Center at a Comprehensive Cancer Center offers the best opportunity for diagnosis and treatment of emergencies and urgent care conditions in cancer patients.
  • [MeSH-minor] Adult. Aged. Analgesics / therapeutic use. Dehydration / epidemiology. Dyspnea / epidemiology. Hemorrhage / epidemiology. Humans. Mexico / epidemiology. Middle Aged. Neoplasms / complications. Neoplasms / epidemiology. Pain / drug therapy. Pain / epidemiology. Patient Compliance. Patient Satisfaction. Retrospective Studies. Shock, Septic / epidemiology. Water-Electrolyte Imbalance / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17224107.001).
  • [ISSN] 0009-7411
  • [Journal-full-title] Cirugía y cirujanos
  • [ISO-abbreviation] Cir Cir
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Analgesics
  • [Number-of-references] 24
  •  go-up   go-down


80. Fisher BL, Schauer P: Medical and surgical options in the treatment of severe obesity. Am J Surg; 2002 Dec;184(6B):9S-16S
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medical and surgical options in the treatment of severe obesity.
  • Weight loss programs, diets, and drug therapy have not shown long-term effectiveness in treating morbid obesity.
  • VBG, a purely restrictive procedure, has fallen into disfavor because of inadequate long-term weight loss.
  • Other procedures currently being offered include laparoscopic adjustable gastric banding; biliopancreatic diversion (BPD), including the duodenal switch (BPD-DS) variation; and distal gastric bypass (DGBP).
  • Laparoscopic adjustable gastric banding with the LAP-BAND system (INAMED Health, Santa Barbara, CA), a restrictive procedure involving placement of a silicone band around the upper stomach, was introduced in the early 1990s and approved by the US Food and Drug Administration for use in the United States in June 2001.
  • [MeSH-minor] Anti-Obesity Agents / therapeutic use. Diet, Reducing. Exercise. Humans. Risk Assessment

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Weight Loss Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12527344.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Obesity Agents
  • [Number-of-references] 66
  •  go-up   go-down


81. Hohenberger P, Ronellenfitsch U, Oladeji O, Pink D, Ströbel P, Wardelmann E, Reichardt P: Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour. Br J Surg; 2010 Dec;97(12):1854-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary tumour location was the stomach in six patients, duodenum in one and small bowel in 16.
  • Fifteen of 16 patients who did not receive adjuvant therapy developed tumour recurrence after a median of 19 months.
  • All patient groups are clear candidates for adjuvant drug therapy.
  • [MeSH-major] Gastrectomy. Gastrointestinal Stromal Tumors / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Mutation. Neoplasm Metastasis. Platelet-Derived Growth Factor / genetics. Prognosis. Risk Factors. Rupture, Spontaneous. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
  • (PMID = 20730857.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Platelet-Derived Growth Factor; 0 / platelet-derived growth factor A
  •  go-up   go-down


82. Rino Y, Imada T, Kabara T, Takahashi M, Shiozawa M, Ohshima T, Hasuo K, Inaba M, Yoneyama K, Yoshikawa T, Yukawa H, Kawamoto M, Tokunaga M, Takanashi Y: How to eradicate Helicobacter pylori using amoxicillin and omeprazole in the remnant stomach. Hepatogastroenterology; 2003 Nov-Dec;50(54):2267-9
Hazardous Substances Data Bank. OMEPRAZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How to eradicate Helicobacter pylori using amoxicillin and omeprazole in the remnant stomach.
  • BACKGROUND/AIMS: We previously investigated the effects of amoxicillin/omeprazole combined therapy on patients who were Helicobacter pylori (H. pylori) positive after gastrectomy for the treatment of gastric cancer, and we determined the difference in amoxicillin dosage between the therapeutic successes and failures.
  • METHODOLOGY: We have previously reported about eradication of H. pylori of remnant stomach as follows.
  • Patients who underwent gastrectomy for the treatment of gastric cancer were enrolled if H. pylori was detected in their remnant stomach after the operation.
  • For the evaluation of H. pylori eradication, endoscopic examination and 13C-urea breath test were performed 12 weeks after the initiation of the treatment.
  • The amoxicillin dosage in the therapeutic successes was compared with that in the therapeutic failures, and we found that the dosage was 14.1 +/- 1.5 and 12.5 +/- 1.5 mg/kg/day in the successes and the failures, respectively.
  • The efficacy of the drug therapy on H. pylori infection was compared between the two groups that one group (Group A) is treated with amoxicillin 750 mg/day for 2 weeks and omeprazole at 20 mg/day for 8 weeks and the other group (Group B) is treated with 1250 mg/day for 2 weeks and omeprazole at 20 mg/day for 8 weeks.
  • CONCLUSIONS: We assumed that the optimal dosage of amoxicillin was over 15.6 mg/kg/day for omeprazole-amoxicillin combined therapy for gastrectomized patients who were H. pylori positive, and the favorable therapeutic effects could be obtained by applying this amoxicillin dosage to the eradication of H. pylori.
  • [MeSH-major] Amoxicillin / administration & dosage. Anti-Bacterial Agents / administration & dosage. Anti-Ulcer Agents / administration & dosage. Gastric Stump. Gastritis / drug therapy. Helicobacter Infections / drug therapy. Helicobacter pylori. Omeprazole / administration & dosage
  • [MeSH-minor] Biopsy. Breath Tests. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Therapy, Combination. Female. Gastric Mucosa / microbiology. Gastric Mucosa / pathology. Gastroscopy. Humans. Male. Prospective Studies. Treatment Failure. Treatment Outcome. Urea

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • Hazardous Substances Data Bank. AMOXICILLIN .
  • Hazardous Substances Data Bank. UREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Hepatogastroenterology. 1999 May-Jun;46(27):2069-73 [10430399.001]
  • (PMID = 14696514.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Clinical Trial; Comment; Comparative Study; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-Ulcer Agents; 804826J2HU / Amoxicillin; 8W8T17847W / Urea; KG60484QX9 / Omeprazole
  •  go-up   go-down


83. Sharma M, Rai K, Sharma SS, Gupta YK: Effect of antioxidants on pyrogallol-induced delay in gastric emptying in rats. Pharmacology; 2000 Feb;60(2):90-6
Hazardous Substances Data Bank. Pyrogallic acid .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The effect of pyrogallol on malondialdehyde (MDA) levels and 5-HT levels in the stomach tissue was also studied.
  • Pyrogallol at a dose of 100 mg/kg, i.p., significantly increased MDA levels and 5-HT levels in the stomach.
  • Pretreatment with a combination of vitamin C and vitamin E (100 mg/kg, p.o.) and glutathione (100 mg/kg, i.v.) significantly ameliorated the rise in stomach tissue MDA caused by pyrogallol but had no significant effect on the rise in 5-HT levels caused by pyrogallol.
  • The result indicate the role of free radicals gastric emptying, and antioxidants may be of potential therapeutic value in disease conditions where free radicals are known to be released and the gastrointestinal effects are observed as symptoms or side effects of drug therapy.
  • [MeSH-major] Antioxidants / pharmacology. Gastric Emptying / drug effects. Pyrogallol / toxicity
  • [MeSH-minor] Animals. Ascorbic Acid / pharmacology. Dose-Response Relationship, Drug. Drug Therapy, Combination. Female. Lipid Peroxidation / drug effects. Male. Malondialdehyde / metabolism. Ondansetron / pharmacology. Rats. Rats, Wistar. Serotonin / metabolism. Serotonin / pharmacology. Serotonin Antagonists / pharmacology. Stomach / drug effects. Stomach / metabolism. Vitamin E / pharmacology

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • Hazardous Substances Data Bank. MALONALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 S. Karger AG, Basel
  • (PMID = 10657758.001).
  • [ISSN] 0031-7012
  • [Journal-full-title] Pharmacology
  • [ISO-abbreviation] Pharmacology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Serotonin Antagonists; 01Y4A2QXY0 / Pyrogallol; 1406-18-4 / Vitamin E; 333DO1RDJY / Serotonin; 4AF302ESOS / Ondansetron; 4Y8F71G49Q / Malondialdehyde; PQ6CK8PD0R / Ascorbic Acid
  •  go-up   go-down


84. Kimura Y, Kikkawa N, Iijima S, Kato T, Naoi Y, Hayashi T, Tanigawa T, Yamamoto H, Kurokawa E: [A new regimen for TS-1 therapy designed to minimize adverse reactions by introducing a one-week interval after each two-week dosing session]. Gan To Kagaku Ryoho; 2002 Aug;29(8):1403-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A new regimen for TS-1 therapy designed to minimize adverse reactions by introducing a one-week interval after each two-week dosing session].
  • It has been reported that the response rate to TS-1 of advanced recurrent gastric cancer was the highest rate (46.5%) of effectiveness among anti-cancer agents, but the incidence of adverse reactions to this drug has been found to be as high as 83.2%, with grade 3 or severer reactions occurring in 20.3% of patients.
  • Taking into consideration the post-marketing survey finding that adverse reactions to the drug first appear 2-3 weeks after the start of oral TS-1 therapy, we attempted a new dosing regimen for this drug, wherein each session of therapy lasted for 2 weeks, with a one-week interval between two consecutive sessions (herein-after called "the 2-week regimen").
  • This regimen was employed based on the expectation that the adverse reactions to the drug would be minimized and that the consecutive dosing period could be prolonged, while keeping the anti-cancer potency at a level similar to that expected with the 4-week dosing regimen with a 2-week interval between sessions (the 4-week regimen).
  • The subjects were 38 patients with advanced or recurrent stomach cancer who were treated with TS-1 at our center between September 1999 and November 2001.
  • These results suggest that the 2-week regimen may allow safer outpatient drug therapy using TS-1 and merits a trial when considering the QOL of patients.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Stomach Neoplasms / drug therapy. Tegafur / administration & dosage
  • [MeSH-minor] Administration, Oral. Adult. Aged. Drug Administration Schedule. Drug Combinations. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12214468.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


85. Gupta AK, Ginter G: Itraconazole is effective in the treatment of tinea capitis caused by Microsporum canis. Pediatr Dermatol; 2001 Nov-Dec;18(6):519-22
Hazardous Substances Data Bank. Itraconazole .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Itraconazole is effective in the treatment of tinea capitis caused by Microsporum canis.
  • Tinea capitis is a relatively common superficial fungal infection in children which requires oral antifungal therapy.
  • Children with mycologic evidence of M. canis tinea capitis were entered into the study and asked to return at week 2 and then every 2 weeks thereafter until cured, with a maximum of 12 weeks of active treatment.
  • Patients were administered either 2, 4, 6, 8, 10, or 12 weeks of treatment.
  • The final follow-up visit was at 12 weeks from the cessation of drug therapy.
  • At week 12 from the cessation of treatment there was complete (clinical and mycologic) cure in all 107 children.
  • Increasing age of the patient correlated significantly with the length of itraconazole capsule therapy (p=0.03).
  • The duration of itraconazole treatment also correlated significantly with the severity of tinea capitis at baseline (p=0.02).
  • These were regarded as being possibly or probably due to the drug in two children (mild transient stomach ache in one and moderate diarrhea in one).
  • The child with diarrhea stopped therapy at week 4 with complete resolution of symptoms.
  • Itraconazole 5 mg/kg/day given either as a capsule or an oral suspension for 4-8 weeks is effective and safe in the treatment of tinea capitis caused by M. canis.
  • [MeSH-major] Antifungal Agents / therapeutic use. Itraconazole / therapeutic use. Microsporum. Tinea Capitis / drug therapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11841643.001).
  • [ISSN] 0736-8046
  • [Journal-full-title] Pediatric dermatology
  • [ISO-abbreviation] Pediatr Dermatol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 304NUG5GF4 / Itraconazole
  •  go-up   go-down


86. Knudsen HE, Ott P: [Treatment of chronic transfusion-requiring watermelon stomach with oral contraceptives]. Ugeskr Laeger; 2002 Jun 17;164(25):3364-6
Hazardous Substances Data Bank. NORETHINDRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of chronic transfusion-requiring watermelon stomach with oral contraceptives].
  • [Transliterated title] Behandling af kronisk transfusionskraevende watermelon stomach med p-piller.
  • Gastric antral vascular ectasia (GAVE), watermelon stomach, is a rare cause of upper gastrointestinal bleeding.
  • [MeSH-major] Estradiol Congeners / administration & dosage. Ethinyl Estradiol / administration & dosage. Gastric Antral Vascular Ectasia / drug therapy. Norethindrone / administration & dosage. Progesterone Congeners / administration & dosage
  • [MeSH-minor] Aged. Blood Transfusion. Drug Therapy, Combination. Gastroscopy. Humans. Male

  • Genetic Alliance. consumer health - Watermelon stomach.
  • Hazardous Substances Data Bank. ETHINYLESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12107954.001).
  • [ISSN] 0041-5782
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Estradiol Congeners; 0 / Progesterone Congeners; 423D2T571U / Ethinyl Estradiol; T18F433X4S / Norethindrone
  •  go-up   go-down


87. Haag C, Ehninger G: [Indications for chemotherapy in cancers of the esophagus, stomach and pancreas]. Z Gastroenterol; 2002 Apr;40 Suppl 1:S68-S70
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Indications for chemotherapy in cancers of the esophagus, stomach and pancreas].
  • [Transliterated title] Indikationen zur Chemotherapie bei Tumoren von Osophagus, Magen und Pankreas.
  • During the last years the chemotherapy in osophageal, stomach and pancreatic cancer demonstrated some success.
  • Radiochemotherapy for esophageal cancer is indicated as neoadjuvant therapy before surgery in locally advanced cancer or in patients with other diseases, which do not allow surgery.
  • In stomach cancer patient there is a clear indication for chemotherapy in metastatic disease and within clinical trials as neoadjuvant chemotherapy in locally advanced cancer.
  • In pancreatic cancer patient the chemotherapy shows less success comparing to other gastrointestinal cancer; it is part of the palliative concept with other therapeutic strategies.
  • [MeSH-major] Esophageal Neoplasms / drug therapy. Pancreatic Neoplasms / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoadjuvant Therapy. Neoplasm Staging. Palliative Care

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11930294.001).
  • [ISSN] 0044-2771
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


88. Baba H, Fujiwara N, Nakamura H, Tanaka K, Kuwabara H, Tamai S, Nakajima K, Goseki N, Shimoda S: [Adjuvant chemotherapy of S-1 and CDDP for undifferentiated adenocarcinoma of the stomach]. Gan To Kagaku Ryoho; 2008 Nov;35(12):2051-3
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adjuvant chemotherapy of S-1 and CDDP for undifferentiated adenocarcinoma of the stomach].
  • Gastrointestinal endoscopy revealed a giant ulcer at distal portion of the stomach.
  • Distal gastrectomy with regional lymph node dissection was carried out.
  • Final pathology report was undifferentiated adenocarcinoma of the stomach, exposing itself to serosa with lymph node metastasis.
  • Postoperative chemotherapy was started using S-1.
  • Undifferentiated adenocarcinoma of the stomach is rare disease.
  • Immunohistochemical staining is useful for a differential diagnosis.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Cell Differentiation. Chemotherapy, Adjuvant. Drug Combinations. Female. Humans. Tomography, X-Ray Computed. Treatment Failure

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106520.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


89. He JM, Pu YD, Cao ZY, Zhu ZD: [Superselective intra-arterial infusion chemotherapy for recurrent cancer in the remnant stomach after partial gastrectomy]. Di Yi Jun Yi Da Xue Xue Bao; 2002 Aug;22(8):734-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Superselective intra-arterial infusion chemotherapy for recurrent cancer in the remnant stomach after partial gastrectomy].
  • OBJECTIVE: To investigate the effect of superselective intra-arterial infusion chemotherapy in the treatment of advanced recurrent cancer in the remnant stomach after previous partial gastrectomy.
  • METHODS: Eighteen patients with advanced recurrent cancer in the remnant stomach that were non-resectable as confirmed in the operations were included in this study, who subsequently received superselective intra-arterial infusion chemotherapy.
  • RESULTS: Improvement of the symptoms to various degrees were achieved in all patients after the therapy, with the total rate of tumor reduction of 77.8% and pathologically confirmed improvement rate of 83.3%.
  • CONCLUSION: Superselective catheterization is effective in treatment of advanced recurrent cancer in the remnant stomach, which can significantly prolong the tumor-bearing survival period of the patients.
  • [MeSH-major] Neoplasm Recurrence, Local / prevention & control. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Drug-Related Side Effects and Adverse Reactions. Female. Follow-Up Studies. Gastric Stump. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Quality of Life. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12376265.001).
  • [ISSN] 1000-2588
  • [Journal-full-title] Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA
  • [ISO-abbreviation] Di Yi Jun Yi Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


90. Li Y, Liang J, Liu WB, Xu XQ, Zhao YR: [Influence of chemotherapy on Th1/Th2 cytokine switching in stomach cancer patients]. Zhonghua Zhong Liu Za Zhi; 2004 Dec;26(12):732-4
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Influence of chemotherapy on Th1/Th2 cytokine switching in stomach cancer patients].
  • OBJECTIVE: To observe the influence of chemotherapy on the switching of Th1/Th2 cytokines in stomach cancer patients.
  • METHODS: Th1/Th2 cytokine genes expressed by peripheral blood mononuclear cells of stomach cancer patients before and after chemotherapy were detected by RT-PCR.
  • RESULTS: The expression of Th2 cytokines was dominant in patients before chemotherapy, and the dominancy became less marked after chemotherapy.
  • CONCLUSION: The immune deviation with Th2 predominance in stomach cancer patients has a tendency to become reversed after chemotherapy.
  • [MeSH-major] Adenocarcinoma. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Interleukins / metabolism. Stomach Neoplasms. Th2 Cells / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15733391.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Interleukins; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 82115-62-6 / Interferon-gamma; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


91. Geh JI, Glynne-Jones R, Kwok QS, Banerji U, Livingstone JI, Townsend ER, Harrison RA, Mitchell IC: Preoperative ECF chemotherapy in gastro-oesophageal adenocarcinoma. Clin Oncol (R Coll Radiol); 2000;12(3):182-7
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative ECF chemotherapy in gastro-oesophageal adenocarcinoma.
  • Epirubicin, cisplatin and continuous 5-fluorouracil (5-FU) infusion (ECF) has been reported to result in high clinical response rates in advanced gastro-oesophageal adenocarcinoma and is currently the 'gold standard' chemotherapy regimen for this tumour site.
  • Despite this, its role as preoperative (neoadjuvant) treatment is unproven and therefore remains under investigation.
  • We report our experience using ECF (intravenous epirubicin 50 mg/m2 and cisplatin 60 mg/m2 every 3 weeks, with continuous infusion of 5-FU 200 mg/m2 per day) as preoperative treatment in locally advanced adenocarcinoma of the lower oesophagus, gastro-oesophageal junction and stomach.
  • Clinical disease progression occurred in six patients (26%) during chemotherapy.
  • Therefore, despite good symptomatic response rates, ECF chemotherapy given in the preoperative setting did not appear to improve the outcome of patients with unresectable or radiologically lymph node-positive gastro-oesophageal adenocarcinoma.
  • The role of ECF chemotherapy in resectable tumours is unclear and is currently under investigation in the randomized MRC Adjuvant Gastric Infusional Chemotherapy (MAGIC) study.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / surgery. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Cisplatin / adverse effects. Epirubicin / administration & dosage. Epirubicin / adverse effects. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Male. Middle Aged. Neoadjuvant Therapy. Survival Rate

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10942336.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; FPEPIR regimen
  •  go-up   go-down


92. Gao CM, Lu JW, Toshiro T, Wu JZ, Cao HX, Chen HQ, Feng JF, Kazuo T: [Polymorphism of methylenetetrahydrofolate reductase and sensitivity of stomach cancer to fluoropyrimidine-based chemotherapy]. Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Dec;25(12):1054-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Polymorphism of methylenetetrahydrofolate reductase and sensitivity of stomach cancer to fluoropyrimidine-based chemotherapy].
  • OBJECTIVE: To investigate the relationship between polymorphisms of the methylenetetrahydrofolate reductase (MTHFR) C677T or A1298C and the response to fluoropyrimidine (5-FU)-based chemotherapy in advanced stomach cancer (SC).
  • All patients were treated with 5-FU-based chemotherapy and DNA of peripheral blood leukocytes was obtained before therapy.
  • The overal response rate to 5-FU-based chemotherapy was 29.3%. (2) The response rate to therapy among MTHFR C677T T/T genotype patients (83.3%) was significantly higher than the C677T C/T genotype (15.2%, chi(2) = 22.27, P = 0.000) or the C677T C/C genotype (8.3%, chi(2) = 23.44, P = 0.000).
  • As compared with patients with C677T C allele, patients with C677T T/T genotype had a 7.64-fold sensitivity to 5-FU-based chemotherapy (adjusted for sex, age, prior adjuvant therapy and chemotherapy program, 95% CI: 3.14 - 18.62).
  • The response rate to therapy among patients with MTHFR A1298C A/A genotype (36.5%) was significantly higher than patients with A1298C C allele (13.0%, chi(2) = 4.19, P = 0.041, adjusted OR = 3.75, 95% CI: 0.94 - 14.87).
  • The response rate to therapy among patients with MTHFR C677T T/T and A1298C A/A genotypes (86.7%) was significantly higher than other groups of C677T and A1298C genotypes (15.0%, Fisher exact: P = 0.000, adjusted OR = 6.57, 95% CI: 2.8 - 15.6). (3) The incidence rates of nausea/vomiting in MTHFR C677T T/T, C/T or A1298C A/A genotypes were significantly higher than other genotypes, but the incidence rates of other treatment-related adverse reaction in MTHFR C677T or A1298C genotypes were not significantly different.
  • CONCLUSION: These results in the present study suggested that the polymorphisms of MTHFR were associated with clinical response to 5-FU-based chemotherapy, suggesting that MTHFR genotypes could identify advanced SC patients that would be responsive to 5-FU-based chemotherapy.
  • [MeSH-major] Drug Resistance, Neoplasm / genetics. Fluorouracil / therapeutic use. Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Stomach Neoplasms / drug therapy. Stomach Neoplasms / enzymology
  • [MeSH-minor] Adult. Aged. Antimetabolites, Antineoplastic / therapeutic use. Female. Genotype. Humans. Male. Middle Aged. Polymerase Chain Reaction. Polymorphism, Restriction Fragment Length

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15769364.001).
  • [ISSN] 0254-6450
  • [Journal-full-title] Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi
  • [ISO-abbreviation] Zhonghua Liu Xing Bing Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2); U3P01618RT / Fluorouracil
  •  go-up   go-down


93. Maeda O, Iwase H, Mamiya N, Nakamura M, Mizuno T, Nishio Y, Ando T, Ina K, Kusugami K: Scirrhous cancer of the stomach which survived for more than five years after neoadjuvant chemotherapy with UFT (uracil and tegafur) and cisplatin. Intern Med; 2000 Mar;39(3):239-44
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Scirrhous cancer of the stomach which survived for more than five years after neoadjuvant chemotherapy with UFT (uracil and tegafur) and cisplatin.
  • A 68-year-old man was diagnosed as having a scirrhous cancer of the stomach.
  • Three courses of uracil and tegafur (UFT)/cisplatin (CDDP) chemotherapy were administered.
  • Histological efficacy of the chemotherapy was judged to be grade 2.
  • Neoadjuvant chemotherapy with UFT and CDDP may have contributed to the favorable clinical outcome in this patient.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Disease-Free Survival. Follow-Up Studies. Gastrectomy. Gastroscopy. Humans. Male. Neoplasm Invasiveness. Tegafur / administration & dosage. Tomography, X-Ray Computed. Uracil / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10772128.001).
  • [ISSN] 0918-2918
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; Q20Q21Q62J / Cisplatin; 1-UFT protocol
  •  go-up   go-down


94. Wilting I, van den Bemt PM, Brenninkmeijer SJ, Spooren PF, Siemons AA, Egberts AC: [Effect of gastric banding on pharmacotherapy: not much known]. Ned Tijdschr Geneeskd; 2007 May 19;151(20):1112-5
MedlinePlus Health Information. consumer health - Weight Loss Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of gastric banding on pharmacotherapy: not much known].
  • [Transliterated title] Invloed van een maagband op farmacotherapie: nog weinig bekend.
  • Following placement of gastric banding, the time that medication remains in the proximal part of the stomach may increase variably.
  • The placement of a gastric band changes the size of the stomach opening and the volume of the functional part of the stomach.
  • Other than oral tablets, alternative formulations of medication, such as liquid or rectal forms are not always available, sometimes the only solution for giving some medication is to ground the tablet finely into powder for oral administration.
  • Patients should receive adequate instructions for intake and information on their therapy so that they do not fail to comply with treatment if tablets have a nasty taste after being ground into powder.
  • Patients who have gastric banding should have medication dosages especially for medication with a narrow therapeutic index followed under strict supervision and have regular blood tests so that any necessary dosage adjustments can be made.
  • At present little data are available to provide a comprehensive overview of the effects of gastric banding on pharmacotherapy.
  • The potential consequences ofgastric banding on pharmacotherapy, together with the increasing frequency of gastric banding surgery, emphasize the need for further research in this field.
  • [MeSH-minor] Delayed-Action Preparations / adverse effects. Dose-Response Relationship, Drug. Drug Administration Routes. Humans. Intestinal Absorption. Tablets, Enteric-Coated / adverse effects. Weight Loss / physiology

  • MedlinePlus Health Information. consumer health - Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ned Tijdschr Geneeskd. 2007 May 19;151(20):1109-11 [17557665.001]
  • (PMID = 17557666.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Delayed-Action Preparations; 0 / Pharmaceutical Preparations; 0 / Tablets, Enteric-Coated
  • [Number-of-references] 24
  •  go-up   go-down


95. Morant R: Neoadjuvant and adjuvant chemotherapy of locally advanced stomach cancer. Onkologie; 2001 Apr;24(2):116-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant and adjuvant chemotherapy of locally advanced stomach cancer.
  • Surgical treatment of locally advanced gastric carcinoma still results in unsatisfactory survival results.
  • The addition of adjuvant chemotherapy has been shown to be of little value and is not considered standard practice.
  • Preoperative chemotherapy, however, has a strong theoretical basis and may achieve significant tumor shrinkage and downstaging and thus allow complete resection of cancers previously judged by the responsible surgeon to be inoperable.
  • However, it has not yet been demonstrated whether preoperative chemotherapy prolongs the survival of patients with potentially resectable cancers.
  • Based on theoretical reasons, preoperative chemotherapy may be expected to be more efficient than postoperative chemotherapy.
  • Differing diagnostic methods, inclusion criteria, and chemotherapy regimens hamper direct comparisons between the trials.
  • Several useful new drugs including taxanes and camptothecins and promising chemotherapy regimens incorporating continuously infused 5-fluorouracil have been introduced recently.
  • Ongoing large randomized clinical trials (MAGIC trial, EORTC, SAKK) currently study the efficacy of preoperative chemotherapy in locally advanced gastric carcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoadjuvant Therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Gastrectomy. Humans. Neoplasm Staging. Randomized Controlled Trials as Topic. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 S. Karger GmbH, Freiburg
  • (PMID = 11441289.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 61
  •  go-up   go-down


96. Innis M, Sandiford N, Shenoy RK, Prussia PR, Zbar A: Carcinoma of the jejunum with multideposit peritoneal seeding, resection and intraperitoneal chemotherapy. West Indian Med J; 2005 Sep;54(4):242-6
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma of the jejunum with multideposit peritoneal seeding, resection and intraperitoneal chemotherapy.
  • Intraperitoneal chemotherapy (IPC) has been shown in non-randomized studies to improve the survival of patients presenting with intraperitoneal metastases from carcinoma of the colon, appendix and stomach and in primary peritoneal malignancies including mesothelioma and pseudomyxoma peritonei, providing that adequate operative cytoreduction can be performed.
  • The patient was treated successfully with immediate postoperative IPC followed by systemic chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Antineoplastic Combined Chemotherapy Protocols. Jejunal Neoplasms / drug therapy. Jejunal Neoplasms / surgery. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Fluorouracil / administration & dosage. Humans. Infusions, Parenteral. Intestinal Obstruction / etiology. Intestinal Obstruction / surgery. Leucovorin / administration & dosage. Male. Middle Aged. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16312191.001).
  • [ISSN] 0043-3144
  • [Journal-full-title] The West Indian medical journal
  • [ISO-abbreviation] West Indian Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Jamaica
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


97. Kaneko T, Konno H, Tanaka T, Kamiya K, Baba M, Oota M, Kondo K, Shouji T, Igarashi A, Nakamura S: [Effective combination chemotherapy for a recurrent case of carcinoma of the remnant stomach]. Gan To Kagaku Ryoho; 2001 Apr;28(4):535-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effective combination chemotherapy for a recurrent case of carcinoma of the remnant stomach].
  • A 69-year-old-man underwent distal gastrectomy for gastric carcinoma in 1988.
  • Another gastric carcinoma was discovered in the remnant stomach in March 1995.
  • Combination chemotherapy with intermittent 5-fluorouracil (5-FU) and low-dose cisplatin (CDDP) was performed.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastric Stump. Neoplasm Recurrence, Local / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Drug Administration Schedule. Fluorouracil / administration & dosage. Humans. Male. Quality of Life

  • Genetic Alliance. consumer health - Stomach carcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11329791.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; CF regimen
  •  go-up   go-down


98. Hsu C, Chen CL, Chen LT, Liu HT, Chen YC, Jan CM, Liu CS, Cheng AL: Comparison of MALT and non-MALT primary large cell lymphoma of the stomach: does histologic evidence of MALT affect chemotherapy response? Cancer; 2001 Jan 1;91(1):49-56
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of MALT and non-MALT primary large cell lymphoma of the stomach: does histologic evidence of MALT affect chemotherapy response?
  • BACKGROUND: Although the clinicopathologic features of low grade gastric MALToma (lymphoma of mucosa-associated lymphoid tissue) recently have been well delineated, the significance of identifying histologic evidence of MALT origin in a primary high grade gastric lymphoma is less clear.
  • The authors sought to address this issue and, in particular, to clarify if MALT and non-MALT primary large cell gastric lymphoma might have a different response to systemic chemotherapy.
  • METHODS: The authors reviewed the pathologic specimens of all patients who had a diagnosis of primary large cell lymphoma of the stomach and who had been treated primarily by systemic chemotherapy in our institutions January 1, 1988-December 31, 1998.
  • All patients received standard systemic chemotherapy including anthracyclines or anthracenedione.
  • Multivariate analysis indicated that response to chemotherapy, disease stage (Stage I and II-1 vs. Stage II-2, III, and IV), and the presence of MALToma features were independent prognostic factors for overall survival.
  • CONCLUSION: The results of this relatively small study series suggested that the presence of histologic features of MALToma in patients with primary large cell gastric lymphoma might have been associated with a better response to systemic chemotherapy and a better prognosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell, Marginal Zone / drug therapy. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11148559.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


99. Wilke H, Stahl M, Vanhoefer U: [Patient with stomach cancer with metastases. What is the value of chemotherapy?]. MMW Fortschr Med; 2003 Nov 27;145(48):39-42
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Patient with stomach cancer with metastases. What is the value of chemotherapy?].
  • [Transliterated title] Magenkrebspatient mit Metastasen. Was leistet die Chemotherapie?
  • In comparison with supportive measures alone, chemotherapy in advanced gastric carcinoma is associated with a significant increase in survival and improvement in quality of life.
  • The following substances are considered to be effective and suitable for combination therapy: 5-FU +/- folic acid, cisplatin, irinotecan, etoposide, taxol, and taxotere.
  • Although "second generation" combinations, such as FAMTX, ELF or cisplatin/5-FU, induced higher remission rates as the "first generation" combinations, they failed to improve survival times to any appreciable extent.
  • Currently accepted standard treatment of metastatic gastric carcinoma is infusional 5-FU + cisplatin or ECF.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Neoplasm Metastasis. Neoplasm Staging. Palliative Care. Quality of Life. Randomized Controlled Trials as Topic. Salvage Therapy. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14724998.001).
  • [ISSN] 1438-3276
  • [Journal-full-title] MMW Fortschritte der Medizin
  • [ISO-abbreviation] MMW Fortschr Med
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] U3P01618RT / Fluorouracil
  •  go-up   go-down


100. Liu YX, Jiang SJ, Kuang TH, Yao YW, Yang JW, Wang YQ: Treatment with yiqi bushen koufuye combined with chemotherapy for preventing postoperative metastasis of stomach cancer--a clinical observation of 28 cases. J Tradit Chin Med; 2009 Dec;29(4):263-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment with yiqi bushen koufuye combined with chemotherapy for preventing postoperative metastasis of stomach cancer--a clinical observation of 28 cases.
  • OBJECTIVE: To study the effect of yiqi bushen koufiuye (oral liquid for invigorating qi and tonifying the kidney) combined with chemotherapy on postoperative metastasis of stomach cancer.
  • METHODS: The 47 cases of postoperative stomach cancer with the syndrome of deficiency of both the spleen and kidney were divided randomly into the treatment group (28 cases), and the control group (19 cases).
  • The control group was treated simply by chemotherapy; while the treatment group, was treated with Yiqi Bushen Koufuye in addition to chemotherapy.
  • The effect was observed 12 months later on local relapse and distal metastasis, the life quality, peripheral hemogram, and immunologic function.
  • RESULTS: The rates of postoperative relapse and metastasis of the treatment group were obviously lower than those of the control group (P < 0.05).
  • The Karnofasky scores, peripheral hemogram and immunologic function of the treatment group were obviously improved in comparison with the control group (P < 0.01 or P < 0.05).
  • CONCLUSION: Yiqi bushen koufuye combined with chemotherapy is effective in preventing postoperative metastasis of stomach cancer, increasing sensitivity and decreasing toxins, and improving the life quality and immunologic function of the patient.

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20112484.001).
  • [ISSN] 0255-2922
  • [Journal-full-title] Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan
  • [ISO-abbreviation] J Tradit Chin Med
  • [Language] ENG
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal
  •  go-up   go-down






Advertisement